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Abstract
Development of a Transient Expression System for the a7 Neuronal 
Nicotinic Acetylcholine Receptor in Mammalian Cells
The chick a7 neuronal nicotinic acetylcholine receptor (nAChR) 
was to be expressed transiently in the mammalian cell line and characterised 
using radioligand and fluorescence label binding assays. This expression 
system was then to be used to screen the responses of point mutated a7 
nAChRs to methyllycaconitine (MLA). These results would then be used to 
determine the structural features of the receptor that make MLA such a potent 
and selective antagonist of the a7 nAChR.
COS-7 cells were transfected with a7 nAChR cDNA using a 
liposome mediated method. Low levels of specific [125l]-aBgt binding (4.6 
fmol/mg protein) was detected occasionally in these cells. Channel blocking 
antagonists, hexamethonium and d-Tubocurarine (dTC), were employed to 
determine their effect on the detectable levels of specific toxin binding.
When included in the post-transfection medium, 50pM 
hexamethonium increased the specific toxin binding to 10.7 fmol/mg protein 
and 10pM dTC to 14.8 fmol/mg protein. Transfected HEK-293 cells exhibited 
significantly greater levels of toxin binding than COS-7 cells, with a similar 
improvement in the presence of 10pM dTC (112.9 fmol/mg protein in the 
absence of dTC and 553.1 fmol/mg protein in the presence of dTC). 
Transfection with the Ca2+ impermeable chimaeric a7-5HT3 receptor, showed
binding similar to that seen in the cells transfected in the presence of dTC. 
This possibly supports the Ca2+ blocking action of the antagonists, however 
the transfected cells do not suffer from decreases in total protein or viable 
cell number (usually associated with Ca2+ cytotoxicity). Thus the increases in 
specific toxin binding may be independent of Ca2+ influx.
MLA inhibited toxin binding in a saturable dose-dependent 
manner, with an IC50 of =1nM, confirming the presence of a7 nAChRs on the 
transfected cells. The FITC-aBgt immunofluorescence assay permitted the 
visualisation of the results recorded for the radioligand assay.
The potency of MLA was investigated by mutating amino acids 
in the ACh binding site of the a7 nAChR, to those in homologous positions in 
the MLA insensitive a1 containing nAChR. Preliminary data showed:
-The <x7E-W mutant produced a similar response to nicotine as that 
seen for the wild-type.
-The a7K-W mutant was insensitive to MLA.
-The a7P-R mutant produced no response to nicotine.
The general conclusions from this study indicate that the presence of channel 
blocking antagonists leads to an increase in specific toxin binding in cells 
transfected by a7 nAChR cDNA.
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Chapter 1.
1. General Introduction
1.1. Neurotransmission and Receptor
The transduction of extracellular signals to the cytoplasm of a 
cell is, in the majority of cases, receptor mediated. For neurotransmitters, 
these receptors reside on the surface of the cell’s plasma membrane. 
Exocytosis of neurotransmitter into the synaptic cleft, occurring within 1ms of
the arrival of an action potential at the synaptic nerve terminal, is one of the
fastest things an animal cell can do (Aimers, 1994). The process by which a 
chemical transmitter message is decoded, by interaction with a specific 
recognition site on a receptor molecule, which in turn elicits a response from 
the cell, is termed neurotransmission (Eadie & Tyrer, 1983). One of the most 
extensively studied neurotransmitters is acetylcholine (ACh). The receptors 
for ACh fall into two broad classes, the muscarinic G protein linked receptors 
(mAChRs) and the nicotinic ligand gated ion channel receptors (nAChRs).
1.2. Ligand Gated Ion Channels
The nAChR belongs to a superfamily of receptors that includes 
GABAa, glycine, serotonin 5HT3, sarcoplasmic reticulum ryanodine and 
glutamate receptors (Ortells & Lunt, 1995; Lees et al, 1994; Maricq et at., 
1991; Stroud eta!., 1990; Miller, 1989). However, the glutamate activated ion 
channel family (AMPA, Kainate & NMDA) and ryanodine family of receptors 
are sufficiently structurally different from the rest of the LGIC superfamily to
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warrant their own subclassifications (Bennett & Dingledine, 1995; Hollmann 
etal., 1994; Seeburg, 1993; Unwin, 1993a; Zorzato etal., 1990).
The nAChRs are themselves a family of receptors that can be 
further subdivided into 3 branches (Wonnacott, 1991, 1986):
1) The neuromuscular junction/Electroplaque (nj/e) nAChR.
2) Neuronal nAChRs that do not bind aBgt.
3) Neuronal nAChRs that do bind aBgt.
aBgt is an elapid curaremimetic neurotoxin isolated from the venom of 
Bungarus multicinctus This polypeptide nicotinic ligand competitively blocks 
(practically irreversibly) the nj/e type nAChR (Lentz & Wilson 1988; Sattelle et 
al., 1983). nAChRs have been shown to be the major antigen in the muscle 
weakening autoimmune disease myasthenia gravis (Asher et al., 1993; 
Souroujon et al., 1993). Many brain acting drugs such as mecamylamine, 
amitriptyline, phencyclidine and trifluoperazine have the nAChR as their 
binding site (Connolly etal., 1992).
Loss of [3H]-acetylcholine and [3H]-nicotine binding to nAChR in 
the brain is associated with loss of cognitive function (Lange et al., 1993; 
Whitehouse et al., 1986). In Alzheimer’s disease, the loss of ligand binding 
seems to be accompanied by a decrease in the cerebral cortex activity of 
choline acetyltransferase and acetylcholinesterase; enzymes involved in 
acetylcholine synthesis and catabolism respectively (Flynn & March, 1986; 
Davis & Maloney, 1976). The cerebral cortex is also the area of the brain that 
contains the greatest density of neurofibrillary tangles (Goedert, 1987; Perry 
etal., 1978), a characteristic histological marker for Alzheimer’s disease. In
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Parkinson’s disease presynaptic nAChRs, present on the cell bodies and 
nerve terminals of the dopaminergic neurones of the nigrostriatal and 
mesolimbic systems, are lost (Prosad et al., 1994; Grady et al., 1992; Rowell 
et al., 1987). Receptor loss within these systems is associated with 
Parkinsonian rigidity and tremor.
It is predicted that by the turn of the century at least 250 million 
premature deaths will have been caused by tobacco usage (Peto et al.,
1992). Nicotine is the addictive drug in tobacco (Balfour, 1994; Jaffe, 1990) 
and nicotine stimulation of dopamine release from mesocorticolimbic 
neurones, has been linked to the ‘reward’ pathways within the brain (Wise, 
1980). This has led to the proposal by Wise and Bozarth (1987) of a 
‘psychomotor stimulant’ theory of addiction. The theory states that the 
physical dependence on nicotine (from smoking or chewing) and other 
addictive substances (eg. alcohol, opiates, benzodiazepines, food, caffeine 
barbiturates and phencyclidine) is secondary to the activation of the ‘reward’ 
pathways through compulsive self administration. There is some recent 
evidence indicating that there may be a genetic predisposition component to 
addiction (Noble et al., 1994). The anxiolytic effects of smoking may be due 
to nicotine decreasing the activity of hippocampal serotonergic systems 
(Benwell etal., 1990).
Nicotine is known to improve performances in tests of attention, 
rapid information processing and other IQ correlates in man (Stough et al., 
1994; Jones et al., 1992; Hindermarch et al., 1980). Use of nicotinic 
antagonists impaired these cognitive abilities (Newhouse et al., 1992). In
3
animals, nicotine improved learning and working memory (Hodges et al., 
1990; Harouturian etal., 1985).
1.3. Neuromuscular Junction/Electroplaque nAChR
1.3.1. The Structure of the Receptor
The neuromuscular junction/electroplaque (nj/e) nAChR is the 
best characterised channel from the nAChR family. The electroplaque refers 
to the electric organs of Torpedo, Electrophorus, Narke and Narcine 
(Ishikawa et al., 1980; Olsen et al., 1973; Schmidt & Raftery, 1973, 1972) 
which are abundant sources of the nAChR (Conti-Tronconi & Raftery, 1982). 
The nj/e nAChR structure and function has been used as a model, on which 
most of the understanding of the other members of the nAChR family and 
LGIC superfamily has been based. The receptor can be considered to be an 
allosteric protein (Monod et al., 1963), with 3 spatially distinct regions: a 
ligand binding region, a cation selective channel and an intracellular region 
that provides sites for the regulation of receptor activity. Despite being 
discrete, events at any one of the regions may affect the activity of the others.
The topography of the nj/e nAChR proposed by Noda et al., 
(1983) and based on the transmembrane arrangements of bacteriorhodopsin 
and Glycophorin A, has held sway since the first subunits were cloned (refs, 
in Mishina etal., 1985; Noda etal., 1982; Sumikawa etal., 1982)
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1.3.2. The Subunits of the Receptor
The nAChR is composed of 4 homologous, but non-identical 
subunits in a pentameric arrangement (Lai & Yu, 1993; Changeux, 1990; 
Brisson & Unwin, 1985) (Figure 1.1). ie. two a-subunits and one of each p, y 
and 5-subunits. However, in the mature neuromuscular junction, the ‘foetal’ y- 
subunit is replaced by the ‘adult’ e-subunit (Mishina et al., 1986). 
Immunological characterisation of the receptor revealed that the a-subunits 
were not adjacent to each other (Fairclough et al., 1983). The latest model 
proposes an arrangement of aPay5 around the channel (Unwin, 1995). In 
Torpedo, the receptors are dimerised via disulphide bridges between the 5- 
subunits (McCrea etal., 1987; Hamilton, 1979).
The general secondary structure is believed to be the same for 
all the subunits. Hydropathy analysis of subunit sequences, led to the belief 
that they were composed of 4 membrane spanning a-helices, termed M1 to 
M4 (Claudio etal., 1983). Current thinking favours a ‘mixed motif model of a- 
helix and p-sheet (Ortells & Lunt, 1994). The evidence comes from direct 
electron density microscopy of frozen receptors and modelling based on 
bacterial B-pentamers (Unwin, 1995, 1993a; Stein etal., 1992; Sixma etal., 
1991).
Using the nicotinic alkylating agent bromoacetyl-[3H]-choline 
bromide, Momoi & Lennon (1982) showed that the a-subunit of the human 
neuromuscular junction nAChR was responsible for the binding of ACh. This 
confirmed the results of Haggerty & Froehner (1981) who demonstrated that 
[125l]-aBgt only bound to the a-subunit of Torpedo electroplaque nAChR.
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More recent work has shown that the y and 5-subunits also contribute to the 
nicotinic ligand binding site (Sine et al., 1994). They play a role in the 
maturation, regulation and cooperativity of the two a-subunit sites (Middleton 
& Cohen, 1991; Sine & Claudio, 1991a; Pedersen & Cohen, 1990). Other 
work has demonstrated that the ay and a5 sites are non-equivalent, with the 
ay site having a 100-300 fold greater affinity for nicotinic ligands than a5 site 
(Dunn et al., 1993; Saedi et al., 1991; Sine et al., 1990). However, the 
nicotinic ligand binding site described by Unwin (1993b) in his electron 
density microscopy images are not located at the ay and a5 interfaces. The 
ligand binding site will be discussed in more detail later.
The (3-subunit does not play a role in the direct binding of 
nicotinic ligands. Its function seems to be to ensure efficient intracellular 
transport of the nascent nAChR, membrane clustering of the receptor and 
coordination of the cooperative mechanism of channel opening, after the 
binding of agonists to the a-subunits (Unwin, 1995; Wheeler et al., 1994; 
Sumikawa & Gehle, 1992; Sine etal., 1990).
1.3.3. The Ion Channel of the Receptor
When [3H]-chlorpromazine, a nAChR non-competitive channel 
blocking drug, was used as a photoaffinity probe it labelled residues a-S248, 
P-S254, P-L257, y-T253, y-S257, y-L260 and 5-S262 (Devillers-Thiery et al., 
1993). All these residues belong to the putative M2 helices of each subunit, 
with a-S248, P-S254, y-S257 and 5-S262 occupying equivalent positions in 
their respective subunits. Other non-competitive affinity labelling agents such
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as trimethylphosphonium and 3-(trifluoromethyl)-3-m-([125l]iodophenyl) 
diazirine (TID) also labelled residues belonging exclusively to M2. 
Trimethylphosphonium labelled residues a-S248, (3-S254 and 5-S262; 
(Hucho, 1986). TID labelled residues 0-L257, J3-V261, 8-L265 and 5-V269 in 
the absence of agonist, (3-S250 and (3-S254 are additionally labelled in the 
presence of agonist (White & Cohen, 1992). [3H]-Meproadifen mustard 
labelled a-E262 at the C-terminal end of M2 (Pedersen et al., 1992). 
However, [3H]-quinacrine azide labelled residues at the N-terminal end of M1 
(Dipaola et al., 1990). This suggests that M1 plays some role in the lining of 
the ion channel and would also support an alternative channel model 
proposed by Akabas etal., (1992).
Single channel conductance experiments performed on nAChRs 
with point mutations in the M2 region revealed the existence of rings of 
charged and polar amino acids (Imoto et al., 1991, 1988). These rings have 
been shown to be responsible for the channel's ability to exclude anions and 
to distinguish between monovalent and divalent cations (Galzi etal., 1992).
Most of the above evidence indicates that the M2 of each 
subunit lines the channel symmetrically and also that M2 has an helical 
secondary structure. These data agree with the Unwin, (1995) model that 
visualises M2 as a ‘kinked’ a-helix, with the kink proposed as the ion gate at 
the level of residue a-L251.
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1.3.4. The ACh Binding Site
It had been originally thought that the disulphide bridged, 15 
residue loop between a-C128 and a-C142 was the site of ACh binding, 
because this site was associated with aBgt binding (Mishina et al., 1986). 
More recent work has shown that this loop, which is present in the subunits of 
nAChRs and other members of the LGIC superfamily (Betz, 1990; Stroud et 
al., 1990) (Figure 1.2), does not form the site of ACh binding. It is, however, 
an essential requirement for correct subunit assembly and intracellular 
transport of the receptor (Sumikawa & Gehle, 1992; Verrall & Hall, 1992). 
Work on the loop from the GABAa receptor has produced similar results 
(Amin etal., 1993).
Photoaffinity and alkylating agents such as ^HJ-DDF and [3H]- 
MBTA have been used as competitive antagonists to identify those residues 
involved in nicotinic ligand binding. The residues labelled fell into three 
different regions of the a-subunit’s N-terminal extracellular domain. In region 
A, W86 and Y93 were identified. In region B, W149 and Y151 were identified 
and in region C, Y190, Y198, C192 and C193 were identified (Galzi et al., 
1990; Dennis et al., 1988; Kao et al., 1984). This has given rise to the 
‘multiple loop’ model for the ACh binding site, with the a-subunit contributing 
at least the 3 identified peptide loops (Galzi etal., 1990, 1991a) (Figure 1.3). 
These observations were similar to those seen for the binding pocket of the 
glycine channel, with residues in positions almost homologous to Y93, W149 
and Y198 being implicated (Schmieden et al., 1992). Mutagenesis studies 
have shown that Y93, Y190 and Y198 are involved in the binding of the
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quaternary N of ACh (Aylwin & White, 1994). Although their interactions are 
of different natures (Sine et al., 1994), the use of aromatic residues in the 
nAChR binding site is similar to the ‘aromatic gorge’ feature seen in the ACh 
binding site of acetylcholinesterase (Sussman etal., 1991).
Most of these labelled residues are conserved at homologous 
positions in all known a-subunits, except a5 (which has not been known to 
form a functional nAChR when expressed in Xenopus oocytes (Boulter et al., 
1990)) which lacks Y93 and Y190 and a8 which lacks Y151. In the model 
proposed by Unwin (1995), each subunit’s N-terminal domain contains what 
appears to be three a-helical rods. From their positions, these a-helices form 
a cavity which is discernibly more open on the two a-subunits. The a-subunit 
cavities are non-identical in shape. These data, along with the recent 
identification of y-W55 and 5-W57 involvement in the agonist binding site 
(Chiara & Cohen, 1992), may help to explain the difference in the 
pharmacologies seen between the sites.
The above labelling data, along with site directed mutagenesis 
established region a180-200 as contributing to the recognition of nicotinic 
ligands (Tomaselli etal., 1991; Mishina etal., 1985). This region includes the 
vicinal cyteines at 192 and 193 that are unique to a-subunits (Aplin & 
Wonnacott, 1994). They are involved in a rare cis half-cystinyl disulphide link 
that due to an energetic strain, can only exist in two conformations (Kellaris & 
Ware, 1989; Kao & Karlin, 1986; Thornton, 1981). The binding of agonist is 
believed to initiate a transition between the conformations. Thus, the vicinal
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cysteines may be acting as a molecular switch that allosterically activates the 
receptor (Kao & Karlin, 1986).
1.4. Neuronal Nicotinic Acetylcholine Receptors That Do Not
Bind aBgt
The subunits making up these nAChRs have been cloned 
through the use of PCR (Polymerase Chain Reaction) or low stringency 
screening of cDNA libraries with known subunit clones. The neuronal 
nAChRs appear to be composed of only two types of subunits, a and p/non-a 
(Nef et al, 1988; Whiting & Lindstrom, 1987a, 1987b). p, is the generally 
accepted nomenclature for the second neuronal nAChR subunit. Affinity 
labelling experiments revealed that the nj/e nAChR nomenclature convention 
of naming subunits in order of increasing molecular weight, was incorrect for 
neuronal nAChRs (Whiting & Lindstrom, 1987a). The experiments showed 
that the ACh binding “P“ subunit, had a greater molecular weight than the 
structural "a" subunit. The nomenclature was swapped (ie. a to p and p to a) 
when the N-terminal protein sequences of the subunits were compared to the 
sequences derived from the cloned subunits’ cDNAs. The neuronal subunits 
are termed retrospectively, a2-9 and P2-4 (ie. the nj/e nAChR a and p 
subunits termed a1 and pi). Non aBgt binding neuronal nAChRs subunits 
have been isolated from species as diverse as human, rat, chicken and 
Drosophila (Sargent, 1993).
The a-subunits have high amino acid homology with one 
another (50%-70%). The p-subunits are as different from each other as they
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are from a-subunits (30%-40%). However, p-subunit genes with the same 
names from different species are highly homologous (>70%). Hydropathy 
analysis of the neuronal nAChR subunit sequences indicate that they share 
the same overall topography, as the nj/e nAChR subunits (refs, in Sargent,
1993). In vitro expression studies using a2, a3 and a4 heterologously 
coexpressed with either p2 or p4, showed that they formed functional nAChR 
that were not blocked by aBgt. This situation may be a simplified one, since 
the proposal of the existence of native nAChRs composed of different a- 
subunits (eg. one receptor containing a3 and a5 as the ACh binding subunits; 
Conroy etal., 1992; Listerud eta!., 1991). With this number of subunits, there 
is the potential for many different forms of neuronal nAChR to exist.
In brain, the predominately expressed subtype of nAChR is 
composed of a4p2 (Whiting & Lindstrom, 1988). It does not bind aBgt and 
has a high affinity for nicotine. This nAChR subtype is believed to be involved 
in many of the presynaptic ACh activated pathways mentioned above, and in 
preterminal modulation of GABAergic axons in rat Interperduncular Nucleus 
(Lena et a!., 1993). The a4p2 nAChR has been identified as the site of action 
of ABT418, a novel nicotinic agonist that, in animal models of the human 
condition of Alzheimer’s disease, treats the cognitive, physical and emotional 
dysfunctions (Arneric etal., 1994; Decker etal,  1994). The analgesic agent 
(+)-Epibatidine, a natural product isolated from the venom of the poison arrow 
frog Epidedobates tricolor, binds potently (Kj 43pM) to a4p2 nAChRs present 
in rat membranes (Sullivan et al., 1994). Upregulation of the a4(32 receptor 
subtype in the brain is a characteristic of addiction to or chronic
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administration of nicotine (Flores et al., 1992). Chronic administration of 
nicotine to Xenopus oocytes and cultured cells expressing a4|32 receptor 
subtype also results in upregulation (Peng et ai, 1994). The observed 
increase in Bmax (receptor density), no change in Kd (affinity) and decrease in 
receptor function (Marks et al., 1983) in the brain of animals chronically 
treated with nicotine is paradoxical, since chronic administration of agonist to 
other receptors (eg. hormone, catecholamine and GABA) normally leads to a 
down regulation of the target receptors (Wonnacott, 1990; Maloteaux et al., 
1987).
Immunological characterisation and channel conductance 
analysis of a4p2 receptors containing mutant subunits, showed the 
composition to be (a4)2(P2)3 (Anand et al., 1991; Cooper et al., 1991). Thus 
neuronal nAChR may possess the same pentameric pseudosymmetric 
quaternary structure as the nj/e nAChR. a3/a5/p4 containing receptors are 
thought to be the primary postsynaptic subtype of nAChR found in ganglionic 
material (Corriveau & Berg, 1993). Receptors composed of these subunits do 
not bind aBgt. Table 1.1 shows the distribution and abundance of the 
subunits within the mammalian CNS.
One problem faced by neuronal nAChR researchers, has been 
the lack of receptor subtype specific ligands (eg. ABT418 for the a4p2 
nAChR subtype). This problem has been overcome, to some extent, by the 
use of a panel of nicotinic ligands in order to identify specific nAChR 
subtypes. nAChRs formed from a2, a3, or a4 subunits in pairwise 
combinations with p2 or p4, were expressed in Xenopus oocytes. Using
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cytisine, nicotine, ACh and DMPP (1,1-dimethyl-4-phenylpiperazinium) as 
nicotinic agonists, Luetje & Patrick (1991) showed that each receptor subtype 
had an unique rank order of potency (Table 1.2). These results demonstrated 
that both a and p subunits played a role in determining nicotinic ligand 
potency. Receptor subtypes containing (32 were almost completely insensitive 
to cytisine, whereas in (34 containing receptor subtypes this ligand was the 
most potent.
Neurotoxin antagonists such as nBgt (neuronal Bungarotoxin, 
isolated as a fraction of Bungarus multicintus venom), NSTX (neosurugatoxin, 
isolated from Babylonica japonica) and LTX-1 (lophotoxin-1, a naturally 
occurring analog of lophotoxin isolated from the sea whip Lophogorgia rigida) 
have also been employed to discriminate between Xenopus oocyte 
expressed receptor subtypes (Luetje et al., 1990; Duvoisin et al., 1989). 
These neurotoxins also demonstrated the involvement of both the a and p 
subunits in determining receptor ligand affinity (Table 1.2). Methods such as 
open channel conductances and channel gating “open-time” distributions 
have been used to distinguish between some of the neuronal nAChR 
subtypes (Papke & Heinemann, 1991; Papke etal., 1989). However, research 
continues to isolate from natural sources or synthesise based on binding site 
data, neuronal nAChR subtype specific ligands.
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1.5. Neuronal Nicotinic Receptors That Do Bind aBgt
1.5.1. The Subunits
Until 5 years ago, the physiological significance of aBgt binding 
sites in the CNS was widely questioned (Clarke, 1992). The aBgt binding 
sites in the brain displayed a pharmacological and biochemical profile similar 
to the nj/e nAChR (Morley & Kemp, 1981; Oswald & Freeman, 1981), but 
aBgt’s inability to attenuate brain nicotinic transmissions highlighted a distinct 
difference (Chiappinelli, 1985; Morley & Kemp, 1981). The confirmation that 
the aBgt binding sites were actually on neuronal nAChRs came with the 
molecular cloning and expression of these receptor subunits. Recently, 
Zhang et al., (1994) and Vijayaraghavan et al., (1992) have shown 
electrophysiologically that neuronal nAChRs that bind aBgt function as 
LGICs.
To date 3 cDNA’s, a7, a8 and a9, have been cloned from 
neuronal nAChRs that bind aBgt (Elgoyhen et al., 1994; Couturier et al., 
1990a; Schoepfer et al., 1990). Their sequence homologies (Table 1.3) 
indicate that these subunits are clearly members of the nAChR family, with all 
the general architectural features of agonist binding subunits (eg. N-terminal 
extracellular cysteine loops and vicinal cysteines). However, the relatively low 
sequence homology between a7, a8 and a1, and a7, a8 and a9 indicates 
that the these 3 subunits belong to two groups. One group contains a7 and 
a8, and the other group contains a9, with both these groups diverging slightly 
from the main phylogenic group containing the other nAChR family subunits. 
Analysis of the intron-exon boundaries positions reveal several differences
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between the a7 and a9 genes, and the genes of the other nAChR family 
subunits (Elgoyhen et al., 1994; Boulter et al., 1990; Couturier et al., 1990a; 
Buonanno et al., 1989; Nef et al., 1988). The gene structure of a8 is as yet 
unknown, since it has only been isolated as a cDNA. The human a7 gene is 
located on chromosome 15 (Chini et al., 1994) and the mouse a7 gene on 
chromosome 9 (Anand & Lindstrom, 1992). The chromosomal loci of chick a8 
and rat a9 are as yet unknown.
1.5.2. The Pharmacology of Neuronal Nicotinic Receptors That
Bind aBgt
An important feature that sets the a7, a8 and a9 subunits apart 
from the other nAChR family subunits is their ability to form functional 
homomeric receptors when expressed alone in Xenopus oocytes (Elgoyhen 
et al., 1994; Couturier et al., 1990a; Schoepfer et al., 1990). Homomeric, 
functional expression in Xenopus oocytes has been reported for GABAa, 
glycine and 5HT3 receptor subunits (Green et al., 1995; Schmieden et al., 
1989; Blair et al., 1988). This ability to form homomeric receptors is also 
shared by the invertebrate nAChR subunit ARL2, isolated from the locust 
Schistocerca gregaria (Marshall et al., 1990). Homomeric ARL2 receptors 
also bind aBgt (Amar etal., 1992). Expression of homomeric rat a4 receptors 
in Xenopus oocytes has been reported, but these receptors gave very weak 
responses even to 100pM ACh (Boulter etal., 1987).
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1.5.2.1. The a7 and a8 Containing nAChRs
Keyser et al., (1993) showed that chick retina contained 3 
subtypes of nAChR that bound aBgt:
1) A neuronal nAChR containing a7
2) A neuronal nAChR containing a7 and a8
3) A neuronal nAChR containing a8
These three receptor subtypes were also found in chick brain, but in different 
proportions. In retina, the a8 containing nAChR predominated, accounting for
=69% of aBgt binding. The remaining aBgt binding in the retina could be
attributed to the a7 (14%) and a7/a8 (17%) nAChRs. The a7 containing 
nAChR predominated in brain, accounting for ^75% of aBgt binding. The a8 
(9%) and a7/a8 (15%) nAChRs accounted for the remaining binding. 
However, it should be noted that only 80-90% of the total aBgt binding could 
be precipitated from the various tissue extracts. The =10% unaccounted aBgt 
binding may indicate the existence of as yet unknown members of the 
neuronal aBgt binding group (Gotti etal., 1994).
Sucrose density gradients indicate that the a7 homomeric 
nAChR is a pentamer of a7 subunits, like the nj/e nAChR (Anand et al., 
1993a). It is assumed that the homomeric a8 nAChR is also a pentamer of a8 
subunits. Although there are many similarities in pharmacology between the 
homomeric a7 and a8 nAChRs and the native a7, a8 and a7/a8 nAChRs, the 
presence of homomeric neuronal a7 and a8 nAChRs seems unlikely. The 
immunoisolated native a7 and a7/a8 nAChRs both contained an
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uncharacterised Mr 52,000 protein (Gotti et al., 1994). This protein may 
influence the pharmacological properties of the native receptors.
Table 1.4a shows some of the pharmacological characteristics 
of the homomeric and native a7 and a8 containing nAChRs. Native a8 
nAChRs exhibit two classes of binding site, an high affinity site and a low 
affinity site. The native a8 high affinity site has a significantly higher affinity 
for most nicotinic ligands than native a7 nAChRs (Gerzanich et al., 1994; 
Anand et al., 1993b). The homomeric a8 nAChR exhibits only a single 
binding site. The pharmacology of this binding site for nicotinic ligands, lies in 
between the high and low affinity binding sites on the native a8 nAChR. Both 
homomeric and native a7 and a8 nAChRs are blocked by atropine, a 
classical mAChR antagonist and strychnine, a classical glycine receptor 
antagonist. Both a7 and a8 homomeric nAChRs are virtually irreversibly 
blocked by aBgt and nBgt.
1.5.2.2. The a9 Containing nAChRs
The pharmacology of the a9 nAChR is the most enigmatic of the 
homomeric nAChRs. When expressed in Xenopus oocytes, homomeric a9 
nAChRs respond to ACh with an EC5o of 10pM. This puts its affinity for ACh 
in between homomeric a7 (320pM) and a8 (1.9pM) nAChRs. However, it 
does not respond to the classical nAChR agonists nicotine and cytisine 
(Elgoyhen et al., 1994). Table 1.4b shows the pharmacology of the 
homomeric a9 nAChR. The nicotinic agonist DMPP elicits a small response 
from homomeric a9 nAChRs, similar to that seen for the homomeric a7
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nAChR where it is a partial agonist (Amar et al., 1993; Seguela et al., 1993). 
The mAChR agonist OXO-M (Oxotremorine-M), also elicited a small 
response. The homomeric a9 nAChR’s binding of agonists thus exhibits a 
mixed nicotinic-muscarinic pharmacological profile. When the antagonists are 
considered, this mixed pharmacological profile is confirmed.
Nicotine and muscarine, both agonists amongst their family of 
receptors, block ACh responses, indicating that these ligands bind to the 
homomeric a9 nAChR but do not activate the channel. ACh responses were 
blocked by dTC (d-Tubocurarine) and atropine. Strychnine potently blocked 
ACh responses, with an IC5o of 20nM. This indicates that the ligand binding 
site on the homomeric a9 nAChR may also possess some glycinergic 
characteristics. Whereas homomeric a7 and a8 nAChRs are virtually 
irreversibly blocked by aBgt and nBgt, the homomeric a9 nAChR was only 
transiently blocked even by 100nM concentrations of these toxins.
The pharmacology of the homomeric a9 nAChR is similar to the 
native nAChR identified on chick cochlea hair cells (Fuchs & Murrow, 1992). 
This nAChR is reversibly blocked by aBgt, not activated by nicotine, 
equipotently antagonised by curare and atropine and potently antagonised by 
strychnine. Similar nAChRs have been described on the cochlea outer hair 
cells of cats and guinea pigs (Housley & Ashmore, 1991; Fex & Adams, 
1978). In situ hybridisation of a9 cRNA to rat embryos and adult rat brain 
found no evidence of a9 gene expression in the CNS (Elgoyhen et al., 1994). 
However, a9 gene expression was detected in the pituitary, embryo tongue,
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embryo sternohyoid muscle, nasal epithelium, inner and outer cochlea hair 
cells.
1.5.3. Ca2+ Permeability and Desensitisation of Neuronal nAChRs
That Bind aBgt.
As well as gating Na+, neuronal nAChRs are very permeable to 
Ca2+ (Sargent, 1993; Vernino et al., 1992). This also true of Xenopus oocyte 
expressed homomeric a7, a8 and a9 nAChRs (Elgoyhen et al., 1994; 
Gerzanich et al., 1994; Bertrand et al., 1993; Galzi et al., 1992). The 
permeability ratio of Ca2+:Na+ (Pca:PNa) for nj/e nAChRs is between 0.1 to 0.3 
(Dwyer et al., 1980). A Pca:PNa value of 20 has been reported for the rat 
homomeric a7 nAChR (Seguela etal., 1993). This is greater than the PCa:PNa 
value of 10.6 reported for the NMDA glutamate receptor (Mayer & Westbrook, 
1992), a receptor regarded as one of the main pathways of promoting 
neuronal Ca2+ influx (Mulle et al., 1992). It is believed that both a8 and a9 
nAChRs share a Ca2+ permeability similar to a7 (Elgoyhen et al., 1994; 
Gerzanich et al., 1994). Thus, a substantial fraction of the current carried by 
these homomeric receptors is carried by Ca2+.
Ca2+-dependent Cl' channels have been identified in Xenopus 
oocytes (Boton et al., 1989). The use of Ca2+ free solutions, external and 
internal Ca2+ chelators such as EGTA and BAPTA, Ca2+-dependent Cl' 
channel blockers such as Niflumic and Flufenamic acid (White & Aylwin, 
1990) have demonstrated that Xenopus oocyte expressed nAChR responses 
are heavily contributed to by secondary activation of Ca2+-dependent Cl'
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channels (Elgoyhen et al., 1994; Gerzanich et al., 1994; Amar et al., 1993; 
Seguela etal., 1993). In single channel experiments, Ca2+ is known to directly 
allosterically modulate native nAChRs by increasing the frequency of channel 
opening without changing the duration of channel opening (Vernino et al., 
1992). Ca2+ may also indirectly modulate neuronal nAChR action by setting in 
motion an enzyme cascade, ending with the desensitisation of the nAChR 
through its phosphorylation (Swope etal., 1992; Huganir & Greengard, 1990; 
Huganir etal., 1986).
Desensitised nAChRs are capable of binding nicotinic ligands 
with an increased affinity than in their resting state, but are unable to activate 
the channel (Lena & Changeux, 1993). Figure 1.4 shows a current model of 
the allosteric conformations and transitions of a nAChR. The nAChR can 
exist in several interconvertible states. R is the nAChR in a resting state. A is 
the nAChR in the active state with agonist bound and channel activated. D 
represents one of several desensitised states in which the channel is closed, 
but the affinity for agonist is increased. The change in affinity of the D states 
was predicted by Monod et al., (1965) in their ‘Concerted’ model of allostery. 
This model explains some of the data seen when comparing nAChR 
functional and binding EC5o’s. Binding assays are usually carried out under 
conditions where the nAChRs are in a desensitised state. The difference in 
functional EC5o (ie. the R states affinity for agonist (Stephens, 1994)) and 
binding EC5o may vary by as much as 1-2 orders of magnitude (Gerzanich et 
al., 1994). Site directed mutagenesis on the M2 of homomeric a7 nAChRs 
produced a mutant nAChR with a decreased rate of desensitisation, but with
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an EC50 more than 2 orders of magnitude more sensitive for ACh (Revah et 
at., 1991). This was probably due to the mutation enabling one of the 
desensitised states to activate the channel (Bertrand et at., 1993; Galzi et at.,
1992). However, this model cannot fully explain the mechanisms behind 
mutants with multiple conductance states or mutations permitting antagonist 
to function as agonists (Bertrand etal., 1992).
1.5.4. The Role of Native Neuronal nAChRs That Bind aBgt.
In chick optic tectum expression of a7 containing nAChRs is 
developmentally regulated between stages E5 to E16 (embryonic days 5 to 
16). The level of a7 mRNA increases from E5 and peaks around E12. This 
coincides with the neurogenesis of connections between the optic tectum and 
the brain stem nuclei (Couturier et at., 1990a). Optic tectum a7 mRNA levels 
from E10 onwards correlate with levels of aBgt binding (Couturier et at., 
1990a; Wang & Schmidt, 1976). From neonate to adult, aBgt mRNA levels in 
optic tectum decrease to a low plateau; this coincides with the maturation of 
cholinergic synapses (Wang & Schmidt, 1976).
The permeability to Ca2+ of neuronal nAChRs that bind aBgt 
has been discussed above. The non-synaptic a7 containing nAChRs of chick 
ciliary ganglion are capable of elevating internal Ca2+ levels without activating 
VDCCs (voltage dependent calcium channels) (Rathouz & Berg, 1994; 
Vijayaraghavan etal., 1992). Hence, local Ca2+ dependent events may occur 
within a neurone without the need for depolarisation of the membrane. This is 
similar to the presynaptic neuronal nAChRs described by Wonnacott et al.,
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(1990) that could directly trigger neurotransmitter release, through Ca2+ influx, 
without the need for depolarisation of the terminal. It should be noted that 
Ca2+ plays a fundamental role in the exocytosis of synaptic vesicles (Rubin, 
1974).
Hippocampal a7 containing nAChRs have been recently 
pharmacologically and electrophysiologically characterised (Barrantes et al., 
1995, 1994; Alkondon et al., 1994; Alkondon & Albuquerque, 1993, 1991). 
Blockade of these nAChRs with aBgt led to an increase in the mRNA for the 
neurotrophic factors NGF (nerve growth factor) and BDGF (brain derived 
growth factor) in discrete areas of the hippocampus (Freedman et al., 1993). 
These hippocampal nAChRs are also involved in the gating response to 
repeated auditory stimuli (Luntz-Leyman et al., 1992), the dysfunction of 
which may be associated with the auditory hallucinations experienced by 
some schizophrenia suffers (Freedman etal., 1991). Rearrangements around 
the chromosomal locus of the human a7 gene are associated with mild 
mental retardation and some treatment-resistant epilepsies (Chini et al.,
1993). This condition is mirrored in a strain of seizure susceptible mouse with 
an high density of hippocampal aBgt binding nAChRs. It should be 
remembered that a8 containing nAChRs are also present in the brain (Keyser 
et al., 1993; Schoepfer et al., 1990). Hence, some of the brain functions 
described above may also involve a8 containing nAChRs.
In vitro culture of retina cells in presence of ACh led to a 
decrease in the number of new neurite processes, when compared to the 
control (Lipton et al., 1988). The reverse was seen when the nAChRs were
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blocked with dTC. This mechanism may involve a8 containing nAChRs which 
are the predominant aBgt binding nAChR subtype in the retina. In vitro 
exposure of cultured ciliary ganglion to nicotine, where a7 containing 
nAChRs are present on the neurites and cell bodies (Ravdin et al., 1981), 
causes neurite retraction of up to 35% of its length, when compared to the 
control (Pugh & Berg, 1994). Blockade of these nAChRs with aBgt or dTC 
prevented neurite retraction. All these neurotrophic effects seem to involve 
increasing internal Ca2+ levels through the activation of VDCCs (Pugh & Berg,
1994). These data indicate that a7 and a8 containing nAChRs may have a 
role in neural plasticity by modulating synapse remodelling (Lipton & Kater, 
1989).
The role of a9 containing nAChRs in tongue and stenohyoid 
muscle is unknown, since a9 transcripts seem to be absent in all other 
skeletal muscles (Elgoyhen etal., 1994). The presence of the a9 transcript in 
pituitary (pars tuberalis) may indicate cholinergic involvement in some 
endocrine effects, such as the coordination of pineal hormone and melotonin 
in circadian systems (Wittkowski et al., 1992; Cassone, 1990). Cholinergic 
modulation has been implicated in olfactory receptor neurone potentials 
(Bouvet et al., 1988). This may involve a9, due its location within the nasal 
epithelium. In cochlea, the location of a9 transcripts in outer hair cells 
indicate that there may be cholinergic involvement in the encoding of auditory 
stimuli and protection against acoustic trauma (Elgoyhen etal., 1994; Rajan & 
Johnstone, 1988).
23
Neuronal nAChRs that bind aBgt have been identified as 
functional nAChRs that may play many diverse physiological roles, the 
mechanisms of which are not fully understood.
1.6. Project Aims
Using the nAChR family as models, much of our understanding 
of LGIC structure and function has been inferred through their study. Such 
data indicates that the majority of LGICs are pentameric complexes. The 
subunits forming these complexes seem to share the same overall 
transmembrane topography and architectural features (exceptions to this 
have been mentioned above). The nAChR has been used as a model 
allosteric protein. It demonstrates excellently how events occurring at 
spatially distinct binding sites are coordinated, through mechanisms not fully 
understood, over the quaternary structure of the protein to gate the ion 
channel. Reconstituted channel conductances, patch clamp, immunological 
characterisation, radioligand binding and affinity ligand binding studies on the 
nAChR have revealed some details about the structure and function LGICs.
Research to highlight the key residues involved in nicotine 
ligand binding and hence determine the structure of the ACh binding site, has 
been one of the main goals of the last 10 years. The structural similarities 
between the subunits of the LGIC superfamily, suggests that these key 
residues may be in equivalent positions in the ligand binding subunits across 
the superfamily. Knowledge of the binding site structure would in turn 
feedback into better receptor specific pharmacophore design. A
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pharmacophore is defined as the “specific three dimensional arrangement of 
essential chemical groups common to active molecules, that is recognised by 
a single receptor” (Sheridan et al., 1986). Refinement of the pharmacophore 
model would lead to the design of new ligands to probe the binding site 
further.
Detailed X-ray diffraction or electron microscopy visualisation of 
the binding site is still some time off (Unwin, 1995; Brisson & Unwin, 1984), 
so ligand binding and site directed mutagenesis are still the best tools for 
investigating the ACh binding site’s structure. The nj/e nAChR, due to its 
availability in a rich and convenient source, has been the subject of most 
research in the past (Fuchs et al., 1984). The study of the neuronal nAChRs 
has been more problematic because of their low abundance in the tissues in 
which they are found. Cloning of the neuronal nAChRs’ subunits, along with 
suitable expression systems, has meant that these receptors can now be 
studied without the need to purify them from their native tissues.
This project will look at the functional homomeric channel 
formed by the chick a7 nAChR subunit. The ability to form homomeric 
channels has been exploited when investigating the nature of the charged 
and polar rings flanking the ion channel and the position of the ‘ion gate’ 
(Galzi et al., 1992). Any mutation introduced would be in all the subunits 
making up the receptor channel. The Xenopus oocyte expression system has 
been used for many years to study the expression, function and 
electrophysiology of LGICs (Kay & Peng, 1991). However, this system is 
limited. Proteins are produced only during the lifetime of the injected RNA or
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DNA, hence studies requiring LGICs to be expressed for more than a few 
days are not practical. Since each oocyte must be individually injected, only 
small quantities of LGICs can be produced. Transfecting a cultured cell line 
either transiently or stably with LGICs may be the answer. A transfected 
cultured cell line would provide large numbers of identical cells expressing 
LGICs that are biochemically, pharmacologically and functionally similar to 
those in the cells from which the cDNAs were derived. Subsequently, if 
mutants LGICs were designed and expressed, this system would permit the 
results to be more easily interpreted and explained, with reference to the 
native LGICs.
Methyllycaconitine (MLA) is a potent inhibitor of ACh and 
anatoxin-a binding at the homomeric a7 nAChR (Thomas et al., 1993; 
Wonnacott etal., 1993). Although ACh and anatoxin-a are agonists and MLA 
an antagonist, they must possess a similar pharmacophore in order to 
compete for the same binding site. Hence, data about the key residues 
involved in the binding of MLA could help in the understanding of how 
agonists are bound.
The project was in two parts. 1) To develop a transient 
expression system in a mammalian cell line for the homomeric a7 nAChR. 
This nAChR would then be characterised through the use of radioligand and 
fluorescence labelled binding assays. 2) To explore, through site directed 
mutagenesis, the structural features in the homomeric a7 nAChR critical to 
the potency of the competitive agonist MLA. This would be achieved by
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a) Table of K values for a, p, y and 8-subunits from Torpedo californica. 
The evolutionary relationships among the subunits can be determined by, 
comparing the aligned amino acid sequences and calculating the amino acid 
difference per residue for each pair of mature subunits. K is defined as 
K=M/N, where M is the number of positions at which different amino acids are 
found between the sequences compared, and N the total number of positions 
(modified from Noda et al., 1983). Therefore, the lower the value of K the 
higher the homology between the sequences.
b) Phylogenic tree of the 4 Torpedo subunits. Tree was generated based 
on information from K values (Miyata & Hayashida, 1982), with to, ^ and t2 as 




c) Features of the nAChR. The y/e subunit has been removed for ease of 
viewing. The homologous subunits are arranged in a ring and the central axis 
of this ring makes a pathway (pore) for the ions. The bulk of the protein 
protrudes into synaptic cleft and contains the neurotransmitter binding 
pocket. Charged groups lining the pore screen out wrongly charged ions and 
facilitate the flow of correctly charged ions (data from Unwin, 1995, 1993a)
28
a p 7 5
a 0.00 0.57 0.64 0.63








X  \ J  
\  \ j  „ V f
C ytop lasm ic
en tran ce
29
Human a1 C E I I V T H F P F D Q Q N C
Torpedo a1 C P I A V T Y F P F D w Q N C
Chick a1 C E I I V T Y F P F D Q Q N C
Mouse a1 C E I I V T H F P F D E Q N C
Rat a1 C E T I V T H F P F D E Q N C
Chick a2 C S I D V T Y F P F D Q Q N C
Chick a3 C K I D V T Y F P F D Y Q N C
Chick a4 C S I D V T Y F P F D Q Q N C
Chick a5 C T I D V T F F P F D L Q N C
Rat a6 C P M D I T F F P F D H Q N C
Chick a7 C Y I D V R W F P F D V Q K C
Chick a8 C Y I D V R W F P F D V Q K C
Rat a9 C V V D V T Y F P F D S Q Q C
Torpedo (31 C T I K V M Y F P F D W Q N C
Rat (31 C S I Q V T Y F P F D W Q N C
Chick (32 C K I E V K H F P F D Q Q N C
Rat (33 C T M D V T F F P F D R Q N C
Chick (34 C K I E V K H F P F D Q Q N C
Torpedo y C P I A V T Y F P F D w Q N C
Torpedo 8 C P I N V L Y F P F D w Q N c
Rat s C Y I D V R W F P F D V Q K c
ARL2 (Locust) C E I D V E Y F P F D E Q T c
ALS (Drosophila) C T I D V T Y F P F D Q Q T c
GABA-ot C P M H L E D F P M D A H A c
GABA-(3 C M M D L R R Y P L D E Q N c
Glycine (48K) C P M D L K N F P M D V Q T c
5HT3 (Serotonin) c S L D I Y N F P F D V Q N c
Glutamate (GluR1)* c F I T s P - F P V D T S N Q
Figure 1.2
Alignments of conserved cysteine loops from the LGIC superfamily. 
The most conserved residues are highlighted in bold.
* - From the glutamate receptor family, this GluR1 sequence is the most 
homologous to the cysteine loop sequences seen in the other members of the 
LGIC superfamily (refs in Hollmann & Heinemann, 1994). The glutamate 
receptor subunits lack the conserved cysteine loop, thus reinforcing the case 









A schematic of the ‘multiple loop’ model of the agonist/competitive 
antagonist binding site of the nAChR. The large sphere represents the 
competitive antagonist DDF in all possible orientations. The polypeptide 
chain has been folded so that all labelled residues contact the sphere. The 
putative glycosylation site at N141 is labelled CHO. The residue labelled X 
indicates the possible involvement of residues from the y and 5 subunits in 
the ACh binding site (Chiara & Cohen, 1992). These residues were labelled 
using [3H]d-tubocurarine (dTC) as an affinity ligand (modified from Galzi et 




A = Active state 
D = Desensitised state
Figure 1.4
A model of allosteric conformations of the nAChRs. This model 
described by Lena & Changeux (1993), was based on the ‘Concerted’ model 




o4, p2, p4 High Widespread
a3 Medium Limited: Brain stem motor nuclei, locus
ceruleus thalamus, autonomic ganglia.
a6, p3 Low Restricted: Hippocampus, thalamus
autonomic ganglia.
a5, a2 Very Low Focal: Hippocampus, cortex.
Table 1.1
The relative abundance and distribution of neuronal nAChR subunits 














cc2p2 Nic > DMPP = ACh > Cyt 0 +++ ++
a2p4 Cyt > Nic > ACh > DMPP - - -
a3p2 DMPP = ACh > Nic > Cyt +++ +++ +++
a3p4 Cyt > Nic = ACh = DMPP 0 - -
a4p2 Nic = ACh > DMPP > Cyt + +++ +++
a4p4 Cyt > Nic > ACh > DMPP - - -
Cyt = Cytisine 
Nic = Nicotine
No Data
0 No Blockade of ACh Induced Current
+ Significant Blockade of ACh Induced Current at Toxin Concentration of
1pM
++ <70% Blockade of ACh Induced Current
+++ >70% Blockade of ACh Induced Current
Table 1.2
The pharmacological properties of neuronal nAChR subtypes 
expressed in Xenopus oocytes. For agonists, the rank order of potency was 
determined by Xenopus oocyte responses relative to the response seen with 
30pM ACh. The data for the antagonists is expressed in terms of the toxins’ 
ability to inhibit ACh induced responses in Xenopus oocytes.
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a7c 100 82 38 44 88





c = Chick 
r = Rat 
h = Human
- = Not Determined 
Table 1.3
The sequence identity homologies of the subunits of the neuronal 




* = IC5o of dTC not curare. 
- = No data.
b)
+ = Activates channel.
- = Does not activate channel.
± = 100nM toxin transiently blocks ACh response. 
ACh = Acetylcholine Cyt = Cytisine OXO =
DMP = DMPP Nic = Nicotine Muse!




a) The pharmacological characteristics of homomeric and native a7 and a8 containing nAChRs.
A<gonists (EC50) Antagonist (IC50)
nAChR Subtype ACh Nicotine Cytisine aBgt Curare Atropine Strychnine
Homomeric a7 3.2x10'4M 2.4x10'5M 5.6x10'6M 1.6x10'9M *2.7x10'7M 3.3x10 4M 1.5x10'5M
Native a7 1.6x10"4M 1.3x1 O^M 2.0x1 0'6M 1.9x10‘9M 7.3x1 0'6M 1.2x10'4M 9.0x1 0'6M
Native a 7 -a 8 6.1x10"6M 3.1x 10'7M - 6.1x10'9M *2.6x1 O^M - -
Native
a8
Site 1 3.1x10‘8M 1.2x10'8M 3.5x10'8M 2.2x1 0'8M 7.9x10'7M 5.8x10'7M 2.0x10'6M
Site 2 3.9x1 O^M 1.1x10'5M 9.4x1 0'7M - 6.5x1 0'5M 5.3x1 0'5M 1.8x10"SM
Homomeric a8 1.9x10eM 1.0x10'6M 1.0x10'6M 1.4x10‘9M *1 .8x10'6M 4.0x1 0'7M 8.0x10'7M
b) The pharmacology of the homomeric a9 nAChR.
Agonists Antagonists
EC50 IC50
ACh Nic Cyt 0 X 0 DMP Nic aBgt nBgt Muse Atrop Stry
1.0x10'5M - - + + 30x10'5M ± ± 7.5x1 O^M 1.3x1 O^M 20x10'9M
Chapter 2.
2. Materials And Methods
2.1. Materials
2.1.1. Organisms
Escherichia coli TG1 [SupEAA hsdA5 thi A(lac-proAB) F ’ [fra D 36 
proAB+ iacF /acZAM15; (Gibson, 1984)] were made competent by the CaCI2 
method (detailed below). E. coli DH5a [SupEAA A/acU169 ((|)80/acZAM15) 
hsdRM recA1 endA1 gyrA96 thi-1 re/A1; (Hanahan, 1983)] were made 
competent by the RbCI2 method (detailed below). These strains of E. coli
were used throughout as host strains for cloning. Cell lines COS-7 (ECACC
No. 87021302) and HEK-293 (ECACC No. 85120602) were obtained from the 
PHLS, Porton Down, U.K.
2.1.2. Vectors
FlipCATa7A and the chimaeric a7-5HT3 cDNA were kindly 
provided by M. Ballivet (University of Geneva, Switzerland) and J-L. Galzi 
(Institut Pasteur, France) respectively. pBluescript® II SK+ phagemid 
(GenBank® No. x52328) was obtained from Stratagene Ltd, Cambridge, U.K. 
pRc/CMV was from Invitrogen, R & D Systems Europe Ltd, Abingdon, U.K. 
pMT3 (Swick etal., 1992) was from the Genetics Institute Inc., MA, U.S.A.
2.1.3. Enzymes
Restriction endonucleases and DNA modifying enzymes were 
obtained from Gibco BRL, Uxbridge, U.K. and Boehringer Mannheim, Lewes,
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U.K. RNase A was from Boehringer Mannheim, Lewes, U.K. Sequenase™ 
sequencing kits were obtained from United States Biochemicals, Cleveland, 
OH, U.S.A. Biotaq DNA polymerase was obtained from Bioline U.K. Ltd, 
Finchley, U.K.
2.1.4. Reagents
General reagents and salts for growth media, unless otherwise 
specified, were from Sigma Chemicals, Poole, U.K. Yeast extract, tryptone 
and agar were from Difco Labs, Detroit, U.S.A. or Sigma Chemicals. Agarose 
was from Sigma Chemicals. Phenol was from Rathburn Chemicals Ltd, 
Waterburn, U.K. Oligodeoxyribonucleotide synthesis reagents were from 
Severn Biotech Ltd, Kidderminster, U.K. or Cruachem Ltd, Glasgow, U.K. 
Lipofectin™, LipofectAMINE™, fibronectin and poly-L-lysine were from Gibco- 
BRL. Tissue culture growth media and supplements were from Flow 
Laboratories, Irvine, U.K. Foetal calf serum was from SeraLab. Sequagel™ 
was from National Diagnostics, Atlanta, GA, U.S.A. Deoxyadenosine 5'[a-35S] 
triphosphate and [125l] were from NEN Research Products, Stevenage, U.K. 
Sephadex G-50, G-25 and Sepharose CL-6B were from Pharmacia, Milton 
Keynes, U.K. FITC-aBungarotoxin, aBungarotoxin, d-Tubocurarine Chloride 
Hexamethonium Bromide and Trypan Blue Solution were from Sigma.
2.1.5. Media and Solutions
The composition of media and solutions used in the Methods 
section are given below. Solutions were sterilised either by autoclaving at
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120°C, 1.41KPa for 20 minutes, or by filtering using Millipore 0.22pM syringe 
filters. All solutions were stored at room temperature in colourless glass or 
plastic bottles, unless otherwise stated.
2.1.5.1. COS-7, HEK-293 and Bacterial Cell Growth Media 
DMEMfl (for general growth of COS-7 cells)




10% (v/v) FCS (heat inactivated)
DMEM/F12n (for general growth of HEK-293 cells)
50/50 mix of DMEM/Ham’s F12 (including Glutamax I)
10U/ml Penicillin
10pg/ml Streptomycin
10% (v/v) FCS (heat inactivated)
DMEMt and DMEM* (for transfection and binding assay)
DMEM
2mM Glutamine
DMEM/F12t and DMEM/F12a (for transfection and binding assay)
50/50 mix of DMEM/Ham’s F12 (including Glutamax I)
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LB Broth
0.1% (w/v) Tryptone 
0.5% (w/v) Yeast-Extract 
0.1% (w/v) NaCI
SOB Broth
0.2% (w/v) Tryptone 
0.05% (w/v) Yeast-Extract 


















15% (v/v) Glycerol 
pH6.8 (KOH)
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Both solutions were then filter sterilised
2.1.5.3. Agarose Gel Electrophoresis Solutions 
0.5x TBE Buffer
44.5mM Tris\Orthoboric Acid (pH8.0)
1.25mM EDTA
10x Loading Buffer
50% (v/v) Gluteraldehyde 
0.25% (w/v) Bromophenol Blue 
0.25% (w/v) Xylene Cyanol
2.1.5.4. DNA Isolation Solutions 
GTE Buffer
25mM Tris\HCI (pH 8.0)
10mM EDTA 
50mM Glucose
Standard Lysis Buffer 
200mM NaOH 
1% (w/v) SDS 















1:4 Dilution of Reaction Buffer (with distilled water) 
1% (w/v) BSA
Chloramine-T Solution
5% (w/v) Chloramine T (in Reaction Buffer)
Made up just prior to use.
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Sodium Metabisulphite
0.08% (w/v) Na2S20 5 (in Reaction Buffer)
Made up 1:4 Dilution in Reaction Buffer just prior to use.
Kl
1% (w/v) Kl (in Reaction Buffer)
Made up just prior to use.
2.1.5.6. Protein Determination Solutions 
Lowrv Solution A
2% (w/v) Na2C0 3  
0.4% (w/v) NaOH 




2.1.5.7. Fluorescence Assay Solutions 
0.2M Phosphate Buffer
0.8% (w/v) KH2P 04 




48ml Hot Distilled H20  (60°C)
4g Paraformaldehyde 
10-12 drops 1M NaOH 
50ml 0.2M Phosphate Buffer 
The solution was filtered through Whatman No.1 filter paper.
2.1.5.8. General Solutions
Chloroform 24:1 (v/v) Chloroform:isoamylalcohol
Phenol Obtained distilled and stored at 4°C, equilibrated
with 2vols. 50mM Tris/HCI pH8.0. Stored in the 
dark at -20°C.
Phenol/Chloroform Equal volumes of equilibrated Phenol and
Chloroform/isoamylalcohol. Stored in the dark at 
-20°C
Ethidium Bromide 10mg/ml stock, stored in the dark at 4°C
RNase A (DNase Free) 10mg/ml stock in TE Buffer, incubated at 95°C for
30 minutes and stored at -20°C
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PBS 0.8% (w/v) NaCI
0.02% (w/v) KCI 
0.144% (w/v) Na2HP04 
0.024% (w/v) KH2P04
2.1.6. Equipment
All water used was from the Milli-Q™ reagent grade water 
system from Millipore Corp., Bedford, MA, U.S.A. Oligodeoxyribonucleotides 
were synthesised on an Applied Biosystems 381A DNA Synthesiser. The
DNA amplification was carried out in a PHC-2 from Techne, Cambridge, U.K.
or a DNA Thermal Cycler™ from Perkin-Elmer-Cetus, Norwalk, CT, U.S.A. 
Centrifugation was carried out in an Ole Dich microfuge 154 or a Du Pont 
Instruments RCB5 centrifuge or a Beckmann L5-65 ultracentrifuge. X-ray 
autoradiography film was from Fuji Photo Films Co., London U.K. Film 
cassettes, film processing chemicals, Polaroid film and equipment were 
supplied by Eastman Kodak Co., Liverpool, UK. Tissue culture vessels were 
from Nunc/Gibco-BRL, Paisley, U.K. DNA and amino acid sequence
information was compiled, stored and analysed using the Staden-Plus™ 
package from Amersham International Pic., Aylesbury, U.K. and the ‘gnome’ 
database at the University of Bath, Bath, U.K. [125l]-abungarotoxin was 
counted in a Cobra™ II from Canberra-Packard, Pangbourne, U.K. Statistics 
and graphs were generated using Microsoft Excel® (Ver. 5.0a) from Microsoft 
Corporation, U.S.A., Biosoft Fig.P® (Ver. 6.2) from Fig.P Software
Corporation, U.S.A. and Sigma-Plot from Jandel Scientific GmbH, Germany.
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2.2. Methods
2.2.1. Preparation of Competent Cells
2.2.1.1. CaCI2 Method
Competent E. coli TG1 cells were prepared using the CaCI2 
method described by Sambrook et a!., (1989). A 10f.il aliquot from a glycerol 
stock of E. coli TG1 was used to inoculate 5ml LB broth and grown overnight. 
An 100pl aliquot of this overnight culture was used to inoculate 100ml LB 
broth and grown at 37°C until the OD6oo reached 0.4. The cells were then 
centrifuged at 10,000xg for 10 minutes at 4°C. The supernatant was 
discarded and the pellet resuspended in 20ml ice cold 50mM CaCI2, then 
incubated on "wet" ice for 30 minutes. The cells were pelleted as before and 
resuspended in 2ml ice cold 50mM CaCI2. The cells were ready for 
transformation after 1 hour and up to 15 hours thereafter.
2.2.1.2. RbCI2 Method
Competent E. coli DH5a cells were prepared using a modified 
RbCI2 method described by Perbal (1988). A 10pl aliquot from a glycerol 
stock of E. coli DH5a was taken and grown overnight in 5ml SOB broth. An 
100|xl aliquot of this overnight culture was used to inoculate 50ml SOB broth 
and grown until the OD6oo reached 0.4. The cells were centrifuged in pre­
cooled tubes at 1,000xg for 10 minutes at 4°C. The pelleted cells were 
resuspended in 40ml ice cold RFI and incubated on ice for 5 minutes. Then 
the cells were pelleted as before. The pellet was resuspended in 8ml ice cold 
RFII and incubated overnight on ice. The competent cells were divided into
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100pl aliquots then flash frozen in liquid N2. The competent cells were stored 
at -70°C until required.
2.2.2. Transformation of Competent Cells
2.2.2.1. Transformation of CaCI2 Competent E. coli TG1 
Competent E. coli TG1 cells were transformed with plasmid
DNA or recombinant plasmid DNA using a method based on that described in 
Sambrook et a!., (1989). The DNA sample was mixed with 300pl competent 
cells and kept on ice for 30 minutes. The cells were 'heat-shocked' in a 42°C 
water bath for 3 minutes. Then 1ml prewarmed LB broth was added to the 
cells and they were incubated in a 37°C water bath for 45 minutes. The cells 
were then plated out on LB agar containing ampicillin (100pg/ml) and 
incubated at 37°C for 12-18 hours.
2.2.2.2. Transformation of RbCI2 Competent E. coli DH5a
RbCI2 competent cells were thawed on ice for 15 minutes. The 
sample DNA was added to 50pl cells in pre-cooled eppendorf tubes and. The 
cells were incubated on ice for 30 minutes, "heat-shocked" at 42°C for 90 
seconds, then returned to ice for 1 minute. Three volumes of SOB broth were 
added to the cells and then they were incubated for 1 hour at 37°C in a 
shaking incubator. The cells were then plated out on LB agar containing 
ampicillin (100pg/ml) and incubated at 37°C for 12-18 hours.
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2.2.3. Small-Scale Preparation of Plasmids
2.2.3.1. Standard Alkaline Lysis Method
This method is based on that described by Sambrook et al., 
(1989). Transformants of interest were grown overnight in 5ml LB broth 
containing ampicillin (100pg/ml). An 1.5ml sample of culture was centrifuged 
at 20,000xg for 5 minutes, the rest of the culture was stored at 4°C. The 
supernatant was discarded and the pellet resuspended thoroughly in 100pl of 
GTE. Then 200pl of Standard Lysis Buffer was added and mixed thoroughly. 
Then 150pl of 5M Potassium acetate (pH4.6) was added and mixed 
thoroughly. The white precipitate was centrifuged at 20,000xg for 5 minutes 
and the supernatant decanted and kept. The supernatant was then solvent 
extracted with phenol/chloroform (1:1). The aqueous phase was transferred 
to a fresh tube. The nucleic acids were precipitated from the aqueous phase 
with 1ml absolute ethanol. The pellet was washed in 500pl 70% (v/v) ethanol 
and vacuum dried. The pellet was resuspended in 50pl of sterile distilled 
water and 1pl RNase A was added. This DNA was then used in restriction 
endonuclease digestions.
2.2.3.2. Rapid Method
This method is based on that described be He et al., (1990). 
Transformants of interest were grown overnight in 5ml LB broth containing 
ampicillin (100pg/ml). An 1.5ml sample of culture was centrifuged at 20,000xg 
for 30 seconds, the rest of the culture was stored at 4°C. The supernatant 
was carefully aspirated away and the pellet resuspended/lysed in 100jxl
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Rapid Lysis Buffer. Then 100pl phenol/chloroform (1:1) was added to the 
lysate and this mix was vortexed for 15 seconds. The phases were separated 
by centrifuging at 20,000xg for 1 minute at room temperature. The aqueous 
phase was transferred to a fresh tube, 200pl of absolute ethanol was added 
to this phase and mixed by inverting the tube. The tube was then centrifuged 
at 20,000xg for 10 minutes at 4°C. The supernatant was carefully aspirated 
away. The pellet was washed with 1ml of 70%(v/v) ethanol, centrifuged for 1 
minute as before and the supernatant aspirated as before. The pellet was 
vacuum dried for 5 minutes and redissolved in 30pl TE Buffer. This DNA was 
then used in restriction endonuclease digestions.
2.2.3.3. Promega Wizard™ Minipreps and Wizard™ Clean-Up
These commercially available kits use an affinity resin to isolate 
the DNA from the cell lysate or PCR reaction. The manufacturer's instructions 
were followed using solutions provided with the kits.
2.2.4. Large-Scale Preparation of Plasmids
2.2.4.1. Alkaline Lysis Method Using CsCI and EtBr
This method is also based on the alkaline lysis protocol that is 
described in Sambrook et al., (1989). From the cells stored at 4°C, 500pl was 
used to inoculate 500ml LB broth with ampicillin (100pg/ml). The cells were 
grown overnight, then pelleted by centrifugation at 3,000xg for 20 minutes at 
4°C. The pellet was resuspended in 8ml of GTE. The cells were lysed by 
adding 16ml Standard Lysis Buffer and then incubated on ice for 10 minutes.
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The cell debris was precipitated with 5ml 5M Potassium acetate (pH4.6) and 
then pelleted by centrifuging at 10,000xg for 30 minutes at 4°C. The 
supernatant was decanted and kept. Nucleic acids were precipitated from the 
supernatant with 0.6vols. of propan-2-ol at room temperature, then pelleted 
by centrifugation at 10,000xg for 10 minutes at 4°C. The vacuum dried pellet 
was resuspended in 10ml of sterile distilled water and the volume accurately 
noted. An equal weight (in g) of CsCI was added, with 300pl of 10mg/ml 
Ethidium Bromide (EtBr) and this solution transferred to Beckmann heat 
sealable tubes. The tubes were balanced to within 10mg, sealed and 
centrifuged at 340,000xg for 18 hours.
The lower, supercoiled plasmid band was taken and solvent 
extracted with amylalcohol to remove the EtBr. The aqueous phase was 
diluted with 1ml sterile distilled water and then the DNA precipitated with 
3vols. ice cold absolute ethanol. The vacuum dried pellet was resuspended in 
1ml sterile distilled water, then precipitated with 2ml absolute ethanol plus 
100pl 3M Sodium acetate. The vacuum dried pellet was resuspended in 1ml 
sterile distilled water and precipitated as before. This pellet was resuspended 
in 200pl sterile distilled water.
2.2.4.2. Alkaline Lysis Method Using LiCI
From the cells at 4°C, 100ml LB broth was inoculated, cells 
pelleted and resuspended in 4ml GTE as before. The cells were lysed with 
8ml Standard Lysis Buffer and incubated on ice for 10 minutes. Cell debris 
from the lysate was precipitated with 15ml ice cold 5M Potassium acetate
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(pH4.6) and the suspension incubated on ice for 15-30 minutes. The 
suspension was centrifuged at 1,000xg for 15 minutes at room temperature. 
The supernatant was filtered through muslin into another tube. Nucleic acids 
were precipitated by adding 18ml propan-2-ol and incubating on ice for 30 
minutes. The nucleic acids were pelleted by centrifugation for 30 minutes as 
before and the air dried pellet resuspended in 1 ml TE Buffer. The suspension 
was split between two tubes, 500|il 6M LiCI added to each tube and 
incubated on ice for 15 minutes. The RNA/protein/salt complex was pelleted 
at 20,000xg for 10 minutes at room temperature. The supernatants were split 
between two tubes and 1ml of -20°C absolute ethanol added to each tube 
and incubated at -20°C for 30 minutes. The nucleic acids were pelleted by 
centrifuging for 10 minutes at 20,000xg at room temperature. The pellets 
were then washed in 500pl 70% (v/v) ethanol and repelleted by centrifugation 
as before. The pellets were vacuum dried and collated by resuspension in 
400pl TE Buffer. RNA was removed by the addition of 4\i\ RNase A and 
incubation at 37°C for 30 minutes. The sample was further incubated with 
20pl SDS (10% (w/v)) at 75°C for 10 minutes. Then 420pl 6M LiCI was added 
and incubated for 15 minutes at room temperature before centrifugation as 
before. The supernatant was split between two tubes, 1 ml absolute ethanol 
was added to each tube and the tubes incubated on ice for 30 minutes. The 
DNA was pelleted by centrifugation at 20,000xg for 30 minutes at room 
temperature. The pellets were washed in 500^1 70% (v/v) ethanol, then 
repelleted by centrifugation for 10 minutes at 20,000xg at room temperature. 
The pellets were resuspended in 400jil sterile distilled H20, then solvent
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extracted with an equal volume of phenol/chloroform (1:1). This was followed 
by 2 further equal volume chloroform extractions, then an absolute ethanol 
precipitation. The pelleted DNA was resuspended in 100pl sterile distilled 
H20  and could be used in further procedures.
2.2.5. Determination of Plasmid DNA Concentration, Purity and 
Oligodeoxyribonucleotide Concentration 
DNA concentration was determined in aqueous solution 
spectrophotometrically by measurement of absorbency at 260nm (A jbo), using 
1 absorbance unit = 50pg double stranded DNA per ml. DNA purity was 
assessed spectrophotometrically by measurement of the ratio of absorbance 
A260/A280. A value = 1.8 for double stranded DNA was used as a criteria for 
purity.
Oligodeoxyribonucleotide concentration was determined 
spectrophotometrically by measurement of A260, using 1 absorbance unit = 




Spectrophotometrically determined concentration of sample in 
grammes per litre 
Length of oligodeoxyribonucleotide 






The template DNA (10pg double stranded) was denatured in 
15pl Denaturing buffer (1M NaOHVImM EDTA) at room temperature for 5 
minutes. The denatured DNA was then put down a 400pl Sepharose CL-6B 
column and the eluate stored on ice until required. For each Sequenase™ T7 
polymerase reaction 7pl of the column eluate was used. The kit used the 
"Dideoxyribonucleotide Chain Termination" method based on those described 
by Sanger eta!., (1977) and Messing, (1983). The manufacturer's instructions 
were followed using the solutions provided in the kit and [a-35S]-dATP. Then 
the sequences were separated by electrophoresis in TBE through denaturing 
6% (w/v) acrylamide/urea Sequagel™ gels, at 30mA constant current. Gels 
were fixed and the urea eluted by washing for 30 minutes in 5% (v/v) Acetic 
acid/5% (v/v) Methanol in distilled water. The gels were washed in distilled 
water, dried and placed, still attached to the glass plate, in an 
autoradiography cassette with X-ray film. The film was exposed to the gel for 
at least 16 hours prior to development.
2.2.7. Agarose Gel Electrophoresis
Agarose was dissolved in very hot 0.5x TBE and allowed to cool 
to 50°C. EtBr was added to a final concentration of 500pg/l and the solution 
used to pour horizontal slab gels. In general 1% (w/v) agarose gels were 
poured. Low melting point agarose gels (1% (w/v)) were poured when DNA 
fragments were to be isolated. The DNA samples were separated by 
electrophoresis in 0.5x TBE containing 100pg/l EtBr. The gels were run at
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between 100-150 mA constant current, with HinD\\\ or Psfl digested A,-phage 
DNA as molecular weight markers.
2.2.8. Isolation of DNA Fragments From Agarose Gels
A simple gel filtration method using Sephadex G-50 method was 
employed to recover desired DNA fragments from agarose gels. This method
was as described by Mukhopadhyay and Roth, (1991).
2.2.9. Preparation of Oligodeoxyribonucleotides for Use in PCR
and Sequencing
Specific biotinylated oligodeoxyribonucleotides were 
synthesised using p-cyanoethyl phosphoramidite chemistry on an Applied 
Biosystems DNA synthesiser according to the manufacturer's instructions. 
The oligodeoxyribonucleotides were deprotected and eluted from the solid 
support by incubation with 1ml NH3 solution (d = 0.89g/ml) for 6-18 hours at 
55°C. The NH3 solution was neutralised by the addition of 1ml Acetic acid, 
after incubation at -20°C for 5 minutes. The oligodeoxyribonucleotides were 
precipitated by the addition of 6ml -20°C absolute ethanol and incubation at - 
20°C for 30 minutes. The oligodeoxyribonucleotides were then pelleted by 
centrifugation at 400xg for 5 minutes at room temperature. The supernatant 
was discarded and the pellet washed in 3ml 80% (v/v) ethanol and 
centrifuged as before. The pellet was vacuum dried and resuspended in 1ml 
sterile distilled H20. This suspension was clarified by centrifuging if
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necessary, then the concentration and purity determined prior to storage at - 
20°C.
2.2.10. Polymerase Chain Reaction
The ability to amplify, clone and ultimately sequence trace 
amounts of DNA is provided by PCR (Saiki et al., 1985). This technique 
involves repeated cycles of high temperature denaturation of double stranded 
DNA, followed by primer annealing to the separated strands of DNA and 
primer extension via the use of dNTPs and a DNA polymerase. Since the 
DNA denaturation usually involves temperatures of =95°C, a thermostable 
DNA polymerase must be used. The most common is Taq DNA polymerase 
isolated from the thermophilic bacterium Thermus aquaticus. Taq DNA 
polymerase retains its activity after >30 minutes at 94°C. Using conserved or 
mismatched primers, genes/cDNA can be isolated or site directed 
mutagenesis can be performed using PCR.
The PCR reactions were set up as follows 
1ng Target DNA
1.5-2pM Oligomer Primers
1.25mM dNTPs (dATP, dTTP, dGTP and dCTP)
10pl 10x Taq Polymerase Buffer
Made up to 99.5pl with sterile distilled water.
0.5pl Taq Polymerase (5U/ml)
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The PCR reaction was overlaid with a layer of mineral oil to prevent 
evaporation from the reaction tube. Using 95°C for 60 seconds to denature 
the double stranded DNA, 48°C for 60 seconds to anneal the primers and 
72°C for 90 seconds to extend the primers, the PCR reaction was cycled 30 
times.
2.2.11. Dynal Streptavidin-Coated Magnetic DynaBeads
Dynabeads (20jil) were taken, stuck to the magnet and the 
supernatant removed. The beads were then washed in 50pl Binding Buffer 
(10mM Tris/HCI pH7.5 1mM EDTA 2M NaCI). The beads were stuck to the 
magnet and the supernatant removed, this procedure was repeated. A PCR 
reaction using biotinylated primers, was affinity purified using a Promega 
Wizard™ Clean-up kit. To the eluate from the Promega Wizard™ Clean-up 
kit, 100pl Binding Buffer was added. The streptavidin/biotin interaction was 
allowed to continue for 13-18 hours at 37°C, with agitation. The beads were 
washed twice in 100pl sterile distilled H20  and the first restriction 
endonuclease digestion set up. The digestions were performed at 37°C 
overnight. The beads were washed in sterile distilled H20  as before and the 
second digestion set up. The beads were stuck to the magnet and the 
supernatant, containing the suitably digested fragment, was collected and 
used in the next cloning step.
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2.2.12. Tissue Culture
2.2.12.1. Growing of COS-7 and HEK-293 Cells
COS-7 cells were grown using DMEM as the basic media
component. HEK-293 cells were grown using a 50/50 mix of DMEM and
Ham’s F12 as the basic media component.
2.2.12.1.1. Growing COS-7 Cells From Liquid N2 Stocks
Prewarmed DMEMg (5ml) was placed in a 50ml culture flask 
along with 1ml of defrosted stock COS-7 cells. The cells were then placed in 
a humidified incubator at 37°C, with a 5% (v/v) C02 atmosphere. After 
allowing two hours for cell attachment to culture vessel surface, the media 
was replaced with another 5ml DMEMg. This was to remove the DMSO in the 
freezing medium that would retard normal cell growth. The DMEMg was 
changed every 72-96 hours.
2.2.12.1.2. Growing HEK-293 Cells From Liquid N2 Stocks
A 1ml liquid N2 stock of HEK-293 cells was defrosted quickly at 
37°C and the phial topped up with prewarmed DMEM/F12g. The cells were 
pelleted by centrifuging the phial at 70-80xg for 5 minutes at room 
temperature. The supernatant was carefully aspirated off and discarded, 
while the pellet was resuspended gently in 1ml of prewarmed DMEM/F12g. 
The cell suspension was then added to a 50ml culture flask, containing 5ml of 
prewarmed DMEM/F12g. The cells were then placed in a humidified incubator 
at 37°C, with a 5% (v/v) C02 atmosphere for 48 hours, to facilitate cell
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attachment to the surface of the culture flask. The DMEM/F12g was changed 
every 72-96 hours.
2.2.12.2. Passaging of COS-7 and HEK-293 Cells
When the cells were 95-100% confluent the cells were 
passaged into 250ml flasks. The media was poured off the cells and the 
traces of media removed by washing monolayer with prewarmed PBS. The 
cells were then trypsinised (0.025% (w/v) Trypsin solution, in prewarmed 
PBS) for 5 minutes at 37°C and the trypsinisation halted by the addition of 
10ml of prewarmed DMEMg or DMEM/F12g The cell suspension was then 
centrifuged at 200xg for 5 minutes at room temperature. The supernatant was 
discarded and the pellet gently resuspended in 5ml prewarmed DMEMg or 
DMEM/F12g 1ml of this suspension was then used to seed 20ml of 
prewarmed DMEMg or DMEM/F12g in a 250ml flask.
2.2.12.3. Transfection of COS-7 and HEK-293 Cells
Transfection was based on the cationic liposome-mediated 
method described by Feigner et al., (1987) using DOTMA (A/[1-(2,3- 
dioleyloxy)propyl]-A/,A/,A/-trimethylammonium chloride) or DOSPA (A/-[2-({2,5- 
bis[(3-aminopropyl)amino]-1-oxypentyl}amino)ethyl]-A/,A/-dimethyl-2,3-bis (9- 
octadecenyloxy)-1-propananium trifluoroacetate) as the cationic lipid agents. 
DOTMA and DOSPA were supplied as Lipofectin™ and LipofectAMINE™ 
reagents, respectively. The cells were plated out into 100mm culture dishes 
and when the cells were between 30-50% confluent, the manufacturers
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instructions were followed for transfection. A transfection reagent/DNA 
complex of 4pl/2|ig per 9.6cm2 was used. After a 6 hour incubation with 
DMEMt or DMEM/F12t> transfection was halted by the addition of prewarmed 
DMEMg or DMEM/F12g supplemented with 20% FCS. Relevant toxins and 
channel blockers were added to the cells at this point. Also at this point, 
percentage cell viability was determined using the ‘trypan blue exclusion’ 
method. The next day the cells were trypsinised as before into 
fibronectin/poly-L-lysine coated 35mm, 6 well plates or onto fibronectin/poly- 
L-lysine coated cover slips. Approximately 24 hours after trypsinising, the 
[125l]-aBgt and FITC-aBgt binding assays were performed on the cells.
2.2.12.4. Trypan Blue Exclusion Viable Cell Assay.
Cells to be counted were pelleted by centrifugation at 200xg for 
5 minutes at room temperature. The pellet was resuspended in 1ml PBS, 
200pl of this cell suspension was added to a tube containing 500pl Trypan 
Blue Solution and 300pl PBS. This suspension was mixed thoroughly and left 
to stand for 5 minutes at room temperature. A sample of this suspension was 
used to fill an hemocytometer by capillary action. Viable cells (ie. live cells) 
are not stained by the dye and appear translucent. Non-viable cells (ie. dead 
cells) are stained by the dye and appear black/dark blue in colour. The 
numbers of viable and non-viable cells were counted and noted in 5 squares 
of the hemocytometer, excluding the cells in contact with the upper and right 
borders of the squares. This procedure was repeated on a second aliquot of
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the Trypan Blue/cell suspension. Calculations for total % cell viability were 
then carried out.
V  Viable Cells(Unstained 
Total % Cell Viability^ . * ■ , x 100%y  Cells (Stained & Unstainec)
2.2.13. I1” !] Procedures
2.2.13.1. lodination of aBgt
lodination of aBgt was based on the Chloramine-T method 
described by Urbaniak et a!., (1973). Reaction Buffer (10pl), 20pl aBgt 
(125pM), and 20pl [125l] (0.1mCi/pl) were placed in a tube and the reaction 
started by the addition of 10pl Chloramine-T Solution. After 1 minute at room 
temperature the reaction was stopped by the addition of 750pl Na2S20 5 and 
200pl Kl. The toxin incorporated [125l] and free [125l] were separated on a 25ml 
Sephadex G-25 column, in Column Elution Buffer. Twenty 1ml fractions were 
collected from the column and 5pl of each fraction countered in a y-counter. 
From these results specific activity and % incorporation were determined.
2.2.13.2. [i26l]-aBgt Binding Assay
This assay was based on that described by Gu et al., (1990) 
and Chavez etal., (1992). The growth media was poured off and the traces of 
media removed completely by washing cells three times in 1ml prewarmed 
PBS. Surface expression of toxin binding proteins was determined by 
incubation of cells with 10nM [125l]-aBgt in 500pl DMEMa or DMEM/F12a for 1
61
hour at 37°C. Non-specific binding was determined by the inclusion of 1pM 
"cold" aBgt. Cells were then washed twice in 1ml PBS, then removed from the 
dish surface with 1ml Lowry Solution A. The samples were then counted in a 
y-counter and afterwards used in a protein determination assay.
2.2.14. Protein Determination Assay
This assay was based on the modified Lowry protein 
determination assay described by Markwell et ai, (1978). BSA (1 mg/1 ml, in 
Lowry Solution A) was used to generate a standard curve from 0-200pg of 
protein. One hundred parts Lowry Solution A was mixed with one part Lowry 
Solution B and 1ml aliquots added to 200pl of sample. The solutions were 
mixed and incubated at room temperature for 10 minutes. Folin-Ciocalteu 
reagent was diluted 1:1 with distilled H20  and 100pl of the diluted reagent 
added to each sample. The solutions were mixed and incubated at room 
temperature for 45 minutes, before determining the A750- Linear regression of 
the BSA standard curve was carried out and the protein concentrations of the 
samples determined by the equations generated.
2.2.15. Fluorescence Binding Assay
The cells grown on cover slips were washed twice in 1ml PBS to 
remove all traces of media. The cells were then fixed for 30 minutes at room 
temperature in 1ml Formaldehyde Fixing Solution. The cells were washed 3 
times in 1ml PBS. Total binding was determined by incubating cells with 
100nM FITC-aBgt in PBS. Non-specific binding was determined by
62
incubating cells with FITC-aBgt/1pM aBgt in PBS. The incubation lasted for 
30-40 minutes in an humidified incubator at 37°C, with a 5% (v/v) C02 
atmosphere. The cells were then washed 4 times with 1 ml PBS, mounted with 
glycerol or Vectashield (Vector Labs) and visualised using an inverted Nikon 
‘Diaphat’ microscope under epifluorescent illumination and phase contrast.
2.2.16. Electrophysiology
The homomeric channels were expressed in Xenopus laevis 
oocytes. The oocytes were prepared, injected and voltage clamp recordings 
performed as described in Bertrand etal,  (1991). This work was kindly done 
by M. Amar and S. Wheeler.
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Chapter 3.
3. Characterisation of the Homomeric Chick a7
nAChR Expressed in Mammalian Cell Lines
3.1. Introduction
This chapter will introduce the cell lines, vectors and
antagonists used throughout this work. Then the results of the transfection 
experiments, with reference to the binding assays, will be presented and 
discussed.
3.1.1. The COS-7 Cell Line
The COS-7 cell line was derived from the CV-1 Green monkey 
kidney fibroblast cell line (Gluzmen, 1981), which is permissive for the lytic 
growth of SV40 (Simian Virus 40). SV40 belongs to the Papovaviridae family 
of small DNA genome viruses. There are three genera in the family; 
Papilloma, Polyoma and Vacuolating. SV40 was believed to belong to the 
Vacuolating genus, but has now been classified in the Polyoma genus. CV-1 
cells were infected with an or/-defective (origin-defective) mutant of SV40, 
that coded for the ‘Large T  antigen. Hence, the cell line name COS from CV- 
1, Origin, SV40.
The Mr 90,000 ‘Large T’ antigen is one of SV40’s ‘Early’ gene 
products and has a possible role as a transcription factor (Gluzman et al., 
1980). Mutant SV40 deficient in ‘Large T  antigen cannot, in permissive cells, 
initiate viral DNA synthesis for productive infection, late RNA synthesis or
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neoplastic transformation (Fraenkal-Conrat & Kimball, 1982). COS-7 cells, 
transfected with a vector bearing a functional SV40 or/, would treat the vector 
as an infecting virus. Appropriately introduced cDNA sequences within the 
vector would be transcribed and translated. Since it is a eukaryotic 
expression system most, if not all the post-translational modifications and 
membrane direction procedures should be performed correctly.
3.1.2. The HEK-293 Cell Line
HEK stands for Human Embryo Kidney (ie. the epithelial cell 
source from which the cell line was derived). The HEK cells were transformed 
by exposure to mechanically sheared fragments of human Ad5 (Adenovirus 
type 5) DNA (Graham et al., 1977). The DNA was sheared because, as with 
SV40 and CV-1 cells, HEK cells are permissive for the lytic growth of Ad5. 
Human Ad5 is a member of the Adenoviridae family. There are 2 genera in 
the family Aviadenovirus and Mastadenovirus, to which Ad5 belongs. (Hull et 
al., 1989). HEK-293 cells produce many ‘Early’ gene products, some of which 
act on the AdMLP (Adenovirus Major Late Promoter) (Ginsberg, 1984). HEK- 
293 cells should treat as an infecting Adenovirus, vectors containing the 
AdMLP. Consequently cDNA sequences introduced appropriately in front of 
the AdMLP would be transcribed, translated and post-translationally modified.
3.1.3. Vectors
The a7 cDNA was subcloned from the Flip vector into the
pBluescript II SK+ vector using HinD\\\IBamH\ sites (Figure 3.1). The
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pBluescript II SK+ was used as an transition vector where the a7 cDNA could 
be manipulated and sequenced.
For COS-7 cell expression, the a7 cDNA was subcloned from 
pBluescript II SK+ into the pRc/CMV vector using H/nDIII/Xibal (Figures 3.1 & 
3.2a). The pRc/CMV vector uses a human CMV (Cytomegalovirus) 
‘Immediate Early’ promoter. CMV is a member of the Betavirusherpesviridae, 
a subfamily of the Herpesviridae. Along with its upstream enhancer 
sequences, the ‘Immediate Early’ promoter is unusually strong and competes 
efficiently for RNA polymerase II (Stinski, 1990). The vector also possesses 
the SV40 ori for maintenance within the COS-7 cell line.
Figure 3.2b shows the Swick et al., (1992) pMT3 vector used in 
the HEK-293 expression system. The a7 cDNA was subcloned from 
pBluescript II SK+ into the pMT3 vector using Pst\/Not\ (Figure 3.1 & 3.2b). 
pMT3 has an AdMLP, with flanking SV40 enhancer and tripartite leader 
sequences to increase the efficiency of RNA transcription (Kaufman, 1985). 
Both vectors can be used in Xenopus oocyte expression systems (Amar et 
al., 1993; Swick etal., 1992), enabling comparison between cultured cell- and 
Xenopus oocyte-expressed homomeric a7 nAChRs to be made.
3.2. The Antagonists
Four antagonists were used during this work. aBgt has been 
already mentioned. The remaining three are Hexamethonium, d-Tubocurarine 
(dTC) and Methyllycaconitine (MLA).
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When NMDAR1/NMDAR2A glutamate receptors were 
expressed in cultured cells, cell death resulted in all the transfected cells (Cik 
et al., 1993). This cell mortality was believed to be due to the L-glutamate 
present in the cell culture medium. The L-glutamate activated the expressed 
NMDA receptors permitting unregulated Ca2+ to enter the cells, eventually 
leading to cell death. (Cik et al., 1993; Tymianski et al., 1993a, 1993b). This 
problem was overcome by the inclusion of NMDA glutamate receptor 
antagonists, AP5 (DL-2-amino-phosphonopentanoic acid) and 5,7- 
dichlorokynurenic acid in the post-transfection medium (Cik et al., 1994; 
Rothman & Olney, 1987). This resulted in a 25% increase in cell viability. 
Specific binding of [3H]-MK801 also increased from =100/ binding sites/mg 
protein to 976 binding sites/mg protein.
The a7 containing nAChRs (especially the homomeric a7 
nAChR) have been shown to be very permeable to Ca2+, even more so than 
the NMDA glutamate receptors. Hexamethonium and dTC (Figure 3.3), 
nicotinic antagonists, were included in the post-transfection medium to 
evaluate their effect on the expression of a7 nAChR. MLA has been recently 
isolated and characterised as one of the most potent low Mr molecules to 
discriminate between nj/e nAChRs and aBgt binding neuronal nAChRs 
(Wonnacott ef al., 1993; Sattelle etal., 1989).
3.2.1. Hexamethonium
Hexamethonium, its full name N.N.N.N’.N’.N’-hexamethyM.e- 
hexanediaminium, was developed in 1948 as an ganglionic blocking and
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antihypertensive agent (Burger, 1980). Since 1949, hexamethonium, along 
with the related decamethonium (used as a skeletal muscle relaxant in 
anaesthesia; Paton & Zaimis, 1949), has been used to distinguish between 
neuronal and nj/e nAChRs. Hexamethonium (C6 ) was better at blocking 
autonomic ganglia than decamethonium (C10), hence neuronal nAChRs 
became known as ‘C6 ’ receptors (Sargent, 1993; Paton & Zaimis, 1949). The 
reverse was true at the nj/e nAChRs and these receptors became known as 
‘C10’ receptors. Ascher et al., (1978) showed that hexamethonium worked by 
reversibly blocking the activated channel. This indicated that it was a non­
competitive antagonist.
3.2.2. dTC
dTC was isolated from the tuber and leaves of Chrondrodedron 
tomentosum (King, 1935) and was used initially, like decamethonium, in 
anaesthesia as a skeletal muscle relaxant (King, 1946). dTC seems to inhibit 
the function of AChRs in two fashions.
1) As a competitive antagonist: dTC competed for the same binding 
site as ACh and other competitive nicotinic ligands, such as aBgt and 
carbamylcholine (Pedersen & Cohen, 1990; Blount & Merlie, 1989; Neubig & 
Cohen, 1979).
2) As a non-competitive antagonist: dTC reversibly blockaded nAChRs 
in a voltage dependent manner, similar to the blockade produced by 
histrionicotoxin, a non-competitive nicotinic antagonist (Sattelle et al., 1989; 
David & Sattelle, 1984). Phencyclidine and proadifen, other nicotinic non­
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competitive antagonists, reduce the incorporation of [3H]-dTC into nAChRs in 
the presence of carbamylcholine (Pedersen & Cohen, 1990).
The above information indicates that as well as acting as a competitive 
antagonist, dTC acts as a channel blocker (Shaker et al., 1982; Katz & Miledi, 
1978).
3.2.3. MLA - Methyllycaconitine
Historically, the seeds' extracts of Delphinium, Aconitum and 
Consolida have been used as sources of poisons and medicines (Blagbrough 
et al., 1994a). Today, these plants are held responsible for more cattle 
deaths in North America than any other poisonous plant and several ‘herbal 
medicine’ poisonings of humans (Coates et al., 1994a; Tomlinson et al.,
1993). Pliny the Elder (G. Plinius) in AD77 documented how the topical 
application of pounded ‘Staphis’ (D. staphysagria) “rid the head of lice as well 
as the rest of the body”. MLA (also known as delatine, delsemidine and 
mellicitine) was found to be the principal norditerpenoid toxin extract from D. 
brownii, producing mortality in a broad spectrum of insects (Jennings et al., 
1986; Nambi Aiyar et al., 1979). The endogenous function of MLA is 
unknown, but it has been proposed that it may have a role in protecting the 
plants against insect damage (Sattelle etal., 1989).
MLA has been shown to be a molecule capable of 
discriminating between subclasses of nAChR (Table 3.1). It is a very potent 
inhibitor of aBgt binding nAChRs of the brain (Wonnacott et al., 1993; Ward 
et al., 1990). In rat brain, MLA inhibits aBgt binding with an IC50 of 3.3nM,
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compared to an IC5o of 8.3pM for inhibition of nicotine binding (Macallan et 
al., 1988). This indicates that MLA binds preferentially to the aBgt sensitive 
a7/a8 containing nAChRs, as opposed to the nicotine sensitive a4(32 
containing nAChRs. Work on Xenopus oocyte expressed homomeric a7 
nAChR indicates that MLA is at least as potent at this nAChR, as it is in the 
rat brain aBgt binding nAChR (Wonnacott etal., 1993)
MLA does not affect hippocampal muscarine, GABA or 
glutamate receptors (Alkondon et al., 1992; Ward et al., 1990). This 
emphasises MLA’s receptor specificity. MLA is believed to be a competitive 
antagonist for two principal reasons:
1) In saturation binding assays to hippocampal membranes using [125l]- 
aBgt, MLA increased the nAChR’s kd for the radioligand (ie. decreased the 
receptor’s affinity for [125l]-aBgt) without increasing the Bmax. This is 
characteristic of a competitive antagonist (Wonnacott et al., 1993).
2) In voltage-clamp electrophysiology, MLA produced a voltage 
independent blockade of the nAChR. This is similar to the blockade produced 
by aBgt, a competitive antagonist (Sattelle et al., 1989; David & Sattelle, 
1984).
MLA can be made semi synthetically from lycoctonine by the 
addition of a 2 -(methylsuccinimido) benzoate ester (Figure 3.3) (Blagbrough 
et al., 1994b). MLA, lycoctonine and aconitine share a similar norditerpenoid 
core and consequently all 3 have the ability to block aBgt binding in the brain 
(Table 3.2). However, the potency of the molecule lies in 2- 
(methylsuccinimido) benzoate ester (Hardick et al., (in press)).
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3.3. Results
3.3.1. Radioligand Binding Assay
aBgt was iodinated as described in section 2.2.13.1. lodination 
of aBgt suitable for use in these studies would give >90% incorporation of the 
125l label into the aBgt and a specific activity, for the [125l]-aBgt, of 
=70QCi/mmol. An example of an iodination experiment is shown in Figure 3.4. 
Preliminary experiments were carried out using the COS-7 expression 
system.
The transfection protocol was optimised by varying the 
incubation time of the DNA/transfection reagent complex with the cells, then 
assaying for the % loss in the number of viable cells. Incubation of 
untransfected and sham-transfected cells (ie. sterile H20  replaced the DNA in 
the transfection protocol) in serum free medium, for 6  hours, led to a 3-4% 
increase in cell death in both cases over cells incubated in DMEMg and 
DMEM/F12g. The level of cell death remained the same for transfected cells 
incubated in serum free medium, for 6  hours (ie. 3-4%). However, if 
transfected and sham transfected cells were incubated in serum free media 
for longer than 6  hours, the cell mortality rose to between 12-17%. Whereas, 
the cell mortality of untransfected cells incubated under the same conditions, 
only rose to 6 %. This indicates that the transfection reagent could be 
cytotoxic, but that the cytotoxicity was linked to the duration of cell exposure 
to the reagent. Consequently, 6  hours was taken to be the standard 
incubation time for the transfection COS-7 and HEK-293 cells.
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The [125l]-aBgt binding assay protocols of Gu et al., (1990) and 
Chavez et al., (1992) both used a volume of 200pl for their radioligand 
incubation solutions. During this study, preliminary experiments showed that 
an assay volume of 200pl was not sufficient to cover the bottom of one 35mm 
diameter well of a 6 -well plate, even with gentle agitation. Using volumes of 
300pl, 400|il and 500pl of DMEMa or DMEM/F12a it was demonstrated that a 
volume of 500pl was sufficient to cover the bottom of a 35mm diameter well, 
with gentle agitation.
Once it was established that the assay could detect specific 
binding of toxin, the length of incubation with the radioligand was optimised. 
Alkondon & Albuquerque, (1991) showed that maximal blockade of ACh 
responses in hippocampal neurones, expressing the a7 nAChR, by aBgt took 
50-70 minutes. Transfected cells were incubated for between 60-90 minutes 
(ie. incubation lasted 90 minutes with samples taken every 10 minutes after 
60 minutes) with [125l]-aBgt. There was no statistical significant difference 
between the levels of specific toxin binding seen across this time period 
(Figure 3.5a). Thus the assay incubation volume was 500pl and the assay 
incubation time was 60 minutes. These assay parameters were used 
throughout this study.
Untransfected and sham transfected cells showed no specific 
binding of [125l]-aBgt. The binding assay, when performed on these cells, 
consistently exhibited greater non specific binding counts per minute (cpm) 
than total binding cpm (by between = 300cpm and 2000cpm, depending on 
the age of the iodinated toxin). Such results were taken to demonstrate the
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absence of specific [125l]-aBgt binding throughout this study. Cells transfected 
with a7 cDNA occasionally showed low levels of specific toxin binding, with 
an average of 4.6 fmol/mg protein (Figure 3.5b). Hexamethonium was then 
added to the post-transfection medium, to determine whether this channel 
blocking drug could improve the expression of the a7 nAChR and hence 
increase the amount of specific toxin binding seen. A range of concentrations 
from 10pM to 500pM, was employed. The inclusion of hexamethonium, up to 
a concentration of 50pM, more than doubled the specific binding of toxin to 
cells transfected with the a7 nAChR cDNA (Figure 3.6a). With the inclusion 
of 50pM hexamethonium, the specific binding was 10.72 fmol/mg protein. At 
concentrations greater than 50pM, the levels of detectable specific binding 
were not significantly different from that seen with 50pM Hexamethonium. 
(Figure 3.6a).
The nAChR open channel blocker, dTC, was also employed to 
assess its ability to modulate a7 nAChR expression (Figure 3.6b). A 
concentration of 1 0 pM was used, this is well above the IC5o of the drug on 
homomeric and native a7 nAChRs (see Table 1.4). When 10pM dTC was 
included in the post-transfection medium, the specific toxin binding increased 
to 14.8 fmol/mg protein. As a result of these data from the COS-7 cells, 10pM 
dTC was used in all subsequent COS-7 and HEK-293 cell expression 
experiments.
A chimaeric receptor made from the extracellular N-terminal 
region of the a7 nAChR and the complementary C-terminal region of the 
5HT3 serotonin receptor, was used as a control in both expression systems.
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Unlike the a7 nAChR, the 5HT3 receptor is not permeable to Ca2+ ions, but is 
in fact blocked by them (Eisele et al, 1993; Maricq et al, 1991). Hence, the 
chimaeric a7-5HT3 receptor should display specific binding similar to that of 
the a7 nAChR expressed in the presence of antagonists (Figure 3.7). 
However, the addition of 10pM dTC to HEK-293 cells expressing the 
chimaeric a7-5HT3 did not significantly increase the level of specific toxin 
binding.
The HEK-293 expression system displayed greater specific 
toxin binding of [125l]-aBgt than the COS-7 expression system, when 
transfected under the same conditions. The difference in expression was 
^40-fold when expression in the presence of dTC was compared. Specific 
toxin binding to cells expressing the a7-5HT3 receptor was greater, in both 
systems, than that exhibited by cells transfected with a7 nAChR cDNA alone.
3.3.2. MLA Inhibition
MLA is an <x7 nAChR specific competitive antagonist. Thus, if 
MLA inhibits the specific binding of [125l]-aBgt to cells purporting to express 
a7 nAChRs, it could be concluded that the receptors are indeed the product 
of the transfecting a7  cDNA. The experiments were carried out in both 
expression systems, with 10pM dTC included in the post-transfection medium 
(Figure 3.8). The radioligand binding assay was modified by the inclusion of 
increasing concentrations of M IA (10pM to 1pM) in the ‘total’ and ‘non­
specific’ binding solutions. The M IA  inhibited the specific binding of the toxin 
in a saturable dose dependent manner, with a mean IC50 of 9.9±6.9nM in the
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COS-7 expression system and 0.9±0.1nM in the HEK-293 expression system. 
Both values compare well to MLA’s reported IC5o at a7 nAChRs (Table 3.1). It 
is not known whether the differences in the ICso’s are intrinsic to the 
expression systems. However, these data suggest that the transfected cells 
are expressing receptors with a distinct a7 nAChR character.
3.3.3. FITC-aBgt Binding Assay
The radioligand binding assay detected surface aBgt binding. 
The employment of aBgt conjugated to the fluorescence label FITC, should 
permit the visualisation of this binding. Figures 3.9a-3.9d shows 
photomicrographs of untransfected and transfected COS-7 cells labelled by 
FITC-aBgt, under total and non-specific binding conditions. Untransfected 
cells displayed little difference between total and non-specific toxin binding 
(Figure 3.9a). Similar levels of toxin binding was seen in cells transfected with 
a7 nAChR cDNA in the absence of 10pM dTC (Figure 3.9b).
The inclusion of 10pM dTC in the post-transfection medium of 
a7 nAChR cDNA transfected cells, produced intense total binding 
fluorescence (=98% cells labelled; Figure 3.9c). The presence of excess 
unlabelled aBgt produced levels of non-specific binding, in these cells, 
reminiscent of that displayed in Figures 3.9a & 3.9b. These results show that 
greater levels of toxin specifically bound to cells grown in the presence of 
dTC, than to cells grown in the drug’s absence. The FITC-aBgt binding to 
COS-7 cells transfected with the chimaeric a7-5HT3 receptor cDNA (Figure 
3.9d), was at a level comparable to that seen in Figure 3.9c. These labelling
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data confirm the findings recorded for the radioligand binding assay. Specific 
toxin binding is increased in cells transfected with a7 nAChR cDNA in the 
presence of channel blocking antagonists, in a manner similar to that seen in 
cells transfected with the Ca2+ impermeable chimaeric a7-5HT3 receptor 
cDNA.
3.4. Discussion
The lack of specific binding of aBgt, detected by the radioligand 
and fluorescence binding assays, to untransfected COS-7 and HEK-293 
cells, indicates the absence of endogenous surface expressed aBgt binding 
nAChRs. Thus specific binding of [125l]-aBgt or FITC-aBgt detected on 
transfected cells, from either of these ‘naive’ cell lines, would be due to the 
product of the transfecting cDNA. COS-7 cells transfected with a7 nAChR 
cDNA occassionally exhibited increased, but low levels of specific toxin 
binding when compared to untransfected cells and other aBgt binding cell 
lines (Chini et al., 1992) (Figure 3.7). This suggested that the product of the 
a7 nAChR cDNA (ie. homomeric a7 nAChRs) was reaching the surface of 
these transfected cells and also, that the specific toxin binding of 4.6 fmol/mg 
protein (Figure 3.5b) was too low to be detected visually by the fluorescence 
binding assay (Figure 3.9b). This final suggestion is unsurprising, considering 
reports of iodine radioligand assays being as much as 1500 times more 
sensitive than comparable fluorescence assays (Nairn, 1976).
A previous transient expression study, reported no detectable 
surface expression of the a7 nAChR (Chen & Patrick, 1993). They used anti-
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a7 antibodies in western blots, to demonstrate that the a7 nAChR protein was 
present in the transfected cells. This indicates a possible problem in the 
nascent a7 nAChR’s membrane translocation mechanism. However, the 
protein detected was present at such low levels that if it did reach the cell’s 
surface, it was probably below the sensitivity of conventional ligand binding 
techniques. This was probably the reason for the failure to detect specific 
toxin binding in some of the early expression experiments (Figure 3.7). But 
why should the expression of a7 nAChRs in cultured cells be so low, when 
compared to the expression of other neuronal nAChRs in cultured cells (eg. 
M10 cell line for the a4p2 nAChR; Whiting etal., 1991)
Ca2+ cytotoxicity, caused by a7 nAChRs high Ca2+ permeability 
(Seguela et al., 1993; Vijayaraghavan et al., 1992), could be a reason for the 
low levels of specific toxin binding. In the case of cultured cells transfected 
glutamate receptor cDNA, low expression and binding was due to Ca2+ 
excitotoxicity (Tymianski et al., 1993a; Roth & Olney, 1987). Constituents 
within the cells’ culture medium activated the ion channel and permitted the 
entry of unregulated Ca2+. This led to poor receptor expression and ultimately 
cell death, through mechanisms possibly involving VDCCs and Ca2+ 
dependent secondary messenger pathways (Tymianski et al., 1993c). This 
was overcome by three methods; the addition of antagonists, point mutations 
at the Q/R/N site within the putative reentrant M2 region of the receptor and 
the use of glutamate/glutamine free medium (Bennett & Dingledine, 1995; Cik 
etal., 1994; Tygesen etal., 1994; Mori etal., 1992).
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DMEM and DMEM/F12 are ‘defined’ media and do not contain 
constituents recognised to activate a7 channels. However, the growing 
medium used was ‘complex’, due to its supplementation with 10% (v/v) FCS 
(see DMEMg and DMEM/F12g in Chapter 2). Hence, there exists the 
possibility of constituent(s) of FCS, as yet unidentified, being capable of 
activating a l  nAChRs and permitting Ca2+ entry. The constituent(s) need not 
bind to the ACh site like conventional nicotinic agonists. They may bind 
elsewhere on the N-terminal extracellular domain like the 
acetylcholinesterase antagonist and nicotinic agonist, physostigmine/eserine 
(Lena & Changeux, 1993; Schrattenholz et al., 1993). Physostigmine is 
proposed to bind to neuronal nAChRs in the region of K125 and activate the 
ion channel, even in the presence of desensitising concentrations of ACh 
(Pereira etal., 1993; Kuhlmann et al., 1991). The binding of physostigmine is 
not inhibited by aBgt, MLA and dTC (Kuhlmann et al., 1991; Okonjo et al.,
1991). The existence of a ‘physostigmine like’ channel activator could provide 
and explanation for the previous low toxin binding data, seen in cells 
expressing homomeric a7 nAChRs and grown in the presence of 
desensitising concentrations of nicotine (ie. a concentration of nicotine that 
normally induces an agonist closed form of the receptor; J-L. Galzi, personal 
communication). Thus it would be possible for unregulated Ca2+ to enter cells 
transfected with a7 nAChR cDNA, in the absence of what would be 
considered a conventional nicotinic agonist. This ligand gating of the ion 
channel could be further exacerbated by Ca2+, which is known to allosterically 
potentiate and increase the probability of opening a7 nAChRs (Eisele et al.,
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1993; Vernino et al., 1992). It is possible that this channel activator, like 
physostigmine, stabilises an as yet unidentified active conformational state of 
the nAChR. In this state the ion channel is open with the ACh binding site 
empty. However, the binding site still retains its ability to bind conventional 
nicotinic agonists and antagonists. If correct, a further modification to the 
allosteric transition model proposed in Figure 1.4 would have to be made. 
The effectiveness of the non-competitive anaesthetic dibucaine at inhibiting 
physostigmine activated channels, indicates that channel blockers may be 
employed to improve the specific toxin binding (Okonjo etal., 1991).
The channel blocking antagonist hexamethonium was included 
in the post-transfection medium of COS-7 cells. This drug could restrict Ca2+ 
entry through the channel. Hexamethonium increased the observed specific 
toxin binding in a concentration dependent manner, with the greatest 
increase seen at 50pM (Figure 3.6a). At higher concentrations of 
hexamethonium, the levels of specific toxin binding seen were not statistically 
different to that exhibited at 50pM hexamethonium. This may have been due 
to prolonged exposure of the cells to the drug at these concentrations 
possibly being cytotoxic. The polymethylene bistrimethylammonium salt 
family, to which hexamethonium belongs, are also known to have 
anticholinesterase and antibacterial activity. Hence, hexamethonium may 
interact with cellular functions resulting in the decrease of specific toxin 
binding. It should be noted that 50pM is =40 times less than the IC50 reported 
for hexamethonium at homomeric a7 nAChRs (Anand et al., 1993). However, 
the injected Xenopus oocytes expressing these receptors are not incubated
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with these greater concentrations hexamethonium for more than a few 
minutes.
The inclusion of 10pM dTC in the post-transfection medium of 
transfected COS-7 cells, further increased the specific toxin binding to 14.8 
fmol/mg protein. This level of [125l]-aBgt binding was similar to that seen in 
SK-N-BE neuroblastoma cells, that express native a7 nAChRs (Chini et a!.,
1992). It has been demonstrated that dTC inhibits nAChRs via 2 
concentration dependent routes: as a competitive antagonist at
concentrations of =1pM; as a non-competitive channel blocking antagonist at 
concentrations >5jliM  (Shaker et al., 1982). At a concentration of 10pM, dTC 
should be acting, like hexamethonium, as a channel blocker. If dTC and 
hexamethonium are working in a similar fashion, the relative increases in 
specific toxin binding could be explained by the drugs’ IC5oS. With an IC50 of 
0.27pM at the homomeric a7 nAChR, 10pM dTC would have a greater 
blockading effect than 50pM hexamethonium with an IC5o of 2 mM at the same 
receptor. However, the data could be simply explained by dTC being a more 
efficacious drug than hexamethonium.
HEK-293 cells transfected with a7 nAChR cDNA displayed 
specific toxin binding of 112.9 fmol/mg protein (Figure 3.7). This level of 
binding lies in between the 90 fmol/mg protein, seen in SH-SY5Y 
neuroblastoma cells, and the 150 fmol/mg protein, seen in cultured 
hippocampal neurones and IMR32 neuroblastoma cells, all expressing native 
aBgt binding nAChRs (Barrantes et al., 1995; Chini et al., 1992). The 
inclusion of 10pM dTC in the HEK-293 cells’ post-transfection medium,
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increased the specific toxin binding by =5-fold. This result suggests that the 
increased specific toxin binding seen in both expression systems, in the 
presence of dTC, could be due to the inhibition of the entry of cytotoxic levels 
of Ca2+. Further evidence of specific toxin binding being linked to Ca2+ 
permeability, was possibly supported when COS-7 and HEK-293 cells were 
transfected with the chimaeric a7-5HT3 receptor cDNA.
Ca2+ impermeability is a feature of the 5HT3 receptor’s ion 
channel that the chimaera possesses (Eisele etal., 1993). However, it should 
be noted that a recent report proposed that homomeric 5HT3 receptors are 
Ca2+ permeable (Hargreaves et al., 1994). This conflicts with the previous 
data on homomeric 5HT3 receptors, reported by Eisele et al., (1993), Maricq 
et al., (1991) and Henderson, (1990), that they are Ca2+ impermeable. 
Specific toxin binding was ^2.5 times greater in COS-7 cells and =3.5 times 
greater in HEK-293 cells, than the binding seen in the cells transfected with 
a7 nAChR cDNA alone (Figure 3.7). Based on the reports of Eisele et al., 
(1993) and Maricq et al., (1991), this level of specific toxin binding could be 
attributable to the chimaera’s Ca2+ impermeability. However, another 
explanation for the level of specific toxin binding seen in cell transfected with 
the chimaeric a7-5HT3 receptor, could be that it is expressed and 
translocated to the membrane more efficiently than the a7 nAChR. Thus the 
level of expression of the chimaeric a7-5HT3 seen in this study, would be 
independent of Ca2+ permeability (see Hargreaves et al., 1994). If this is so 
the premiss that unregulated cytotoxic Ca2+ was the cause for the low levels 
of specific toxin binding, was incorrect. Evidence for this comes from the fact
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that Ca2+ cytotoxicity is associated with a decrease in the total protein 
concentration and the number of viable cells within a culture (Cik et al.,
1994). In this study total protein concentrations were between 0.4- 
0.45mg/35mm dish for COS-7 cells and 0.3-0.45mg/35mm dish for HEK-293 
cells (transfected cells, transfected cells in the presence of antagonists and 
untransfected cells). Thus cell death does not seem to be taking place, 
otherwise total protein levels in cells transfected with a7 cDNA alone would 
have been much lower. Hence, an alternative explanation for the increases in 
specific toxin binding, seen when antagonists were included in the post­
transfection medium, could be proposed.
The presence of antagonists may, through a mechanism such 
as that proposed below, lead to more efficient surface 
expression/upregulation of the a7 nAChR. In vivo and in vitro exposure of 
tissues expressing neuronal nAChRs to desensitising levels of agonist, leads 
to an upregulation in the numbers of expressed receptors (Barrantes et al., 
1995; Flores etal., 1992; Wonnacott, 1990). Upregulation seems to require 
the allosteric transition of the receptor from the ‘resting’ to ‘desensitised’ 
states, to go via the ‘activated’ state (Barrantes et al., 1995; Schwartz & 
Kellar, 1985). In this desensitised state, the receptors are functionally 
blocked and upregulation is proposed to occur through decreased receptor 
turnover (ie. via decreased rates of surface receptor co-option and 
degradation) (Peng et al., 1994). The channel activating ligand in the growth 
medium may, like physostigmine, only activate the nAChR without inducing 
desensitisation (Pereira et al., 1993). Thus, the ligand on its own could not
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produce an upregulation in receptor number. The binding of an antagonist 
that stabilises the ‘desensitised’ state of the receptor, could have the same 
‘upregulation’ effect as prolonged exposure to agonist. dTC stabilises the 
‘desensitised’ state of the nAChR (Lena & Changeux, 1993). The a l  nAChR 
expressed in cultured cells and in the presence of 10pM dTC, could have 
undergone the allosteric transitions necessary to produce ‘agonist induced 
like’ receptor upregulation. Hence, as well as by blocking the channel, dTC 
could also be increasing the level of specific toxin binding by inducing 
receptor upregulation. The effect of binding hexamethonium on the nAChR 
conformation is unclear. The lower effectiveness of hexamethonium 
compared to dTC may be explained by this proposed mechanism if, like 
MK801, hexamethonium’s blocking of the channel induces little or no 
conformational change in the nAChR (Stephens, 1994; Ramoa et al., 1990). 
The data from HEK-293 cells expressing the chimaeric a7-5HT3 in the 
presence of dTC, suggests that this mechanism may be unique to the a7 
nAChR.
The validity of this theory could be tested by ligand binding and 
whole cell voltage-clamp recording experiments. The expected results would 
show an increase in Bmax, but no change in the Kd and a decrease in the level 
of receptor function. The presence of the ‘allosteric channel activator1 could 
be screen for using patch clamped a7 nAChR expressing hippocampal 
neurone membranes (like Pereira et al., (1993) when assaying the channel 
activating ability of physostigmine) or membranes from Xenopus oocytes 
expressing the homomeric a7 nAChR.
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However, this transient expression system has determined the 
parameters within which a stably transfected cell line, expressing the 
homomeric a7 nAChR, can be developed.
The HEK-293 expression system exhibited significantly greater 
specific toxin binding than that seen in the COS-7 expression system, when 
transfected under the same conditions. The reasons for this are unknown. 
Statistical comparisons between the expression systems’ % changes in 
specific toxin binding (Figure 3.7), are not significant (with a confidence 
threshold probability of 0.05). Therefore the relative levels of specific toxin 
binding, seen in both expression systems, are statistically similar. This 
suggests that dTC increases the expression of a7 nAChR in COS-7 cells and 
HEK-293 by the same extent. This is mirrored by the statistically similar 
relative levels of specific toxin binding, exhibited by cells transfected with 
chimaeric a7-5HT3 cDNA. These results indicate intrinsic differences 
between the expression systems, rather than in the receptor expressed. 
Further evidence of this was provided when the preliminary experiments 
using the HEK-293 cells were performed, using a7 nAChR cDNA in the 
pRc/CMV vector. The results of the toxin binding assays (not shown) were 
statistically similar to those subsequently produced by the cells using a7 
nAChR cDNA in the pMT3 vector. Hence, this would indicate that the HEK- 
293 cells are better expressers of the a7 nAChR than COS-7 cells. This may 
be due to the HEK-293 cells’ maintenance of a higher vector copy number 
than the COS-7 cell or just a more efficient exogenous protein expression 
apparatus (ie. better transcription, translation, membrane translocation and
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mechanisms). Northern blots or permeabilisation of the cells to look at the 
numbers of receptors in transit to and from the membrane surface, may help 
to reveal more about the differences in expression between the cell lines.
The nicotinic nature of the aBgt binding detected was confirmed 
by the binding of MLA. MLA inhibited specific toxin binding in both expression 
systems with IC5o’s in the same range as those previously reported for the a7 
nAChR. This suggests that the transfected cells COS-7 and HEK-293 cells 
are expressing the purported homomeric a7 nAChR. However, if both 
expression systems are expressing statistically similar receptors, the IC50’s 
should also be similar. The sources and length of storage of the MLA 
samples used during this study could provide a possible explanation. The 
MLA sample used in the COS-7 cell experiments, was slightly older and from 
a different batch from the sample used in the HEK-293 experiments. This 
older MLA sample may have chemically degraded to a less potent form. 
When used experimentally, this sample would give an apparent impression 
that the a7 nAChRs expressed in COS-7 cells, were less sensitive to MLA 
than those expressed in the HEK-293 cells. Hence, providing a possible 
explanation for the differences in the IC5o’s (Figure 3.8). The MLA inhibition of 
specific toxin binding to homomeric a7 nAChRs expressed in COS-7 cells, 
should be repeated with the same batch of MLA used in the HEK-293 
expression experiments and with extra concentration points in the middle of 
the curve. However, the data from this study may provide the first reported 
IC5o for MLA for the homomeric a l  nAChR expressed in a mammalian cell 
line.
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The fluorescence labelling of transfected COS-7 cells (Figure 
3.9) gave visual confirmation of the radioligand binding results. The inclusion 
of 10|xM dTC in the post-transfection medium or transfection with the Ca2+ 
impermeable chimaeric receptor cDNA, led to an increase in the number and 
intensity of FITC-aBgt labelled cells. Thus displaying visually the increase in 
the number of surface expressed homomeric a7 nAChRs. The proportion of 
labelled cells is consistent with the report by Felner et a!., (1987), 
demonstrating the potential of the transfection agent/DNA complex, when 
employed in proportions similar to that above, to interact with virtually all the 
cells to be transfected. Preliminary binding experiments performed on HEK- 
293 cells has exhibited similar results (results not shown).
3.4.1. Summary
COS-7 and HEK-293 cells, when transfected with chick a7 
nAChR cDNA, express low levels of putative homomeric a7 nAChRs. The 
expression of the receptor, in both COS-7 and HEK-293 cells, was increased 
by the addition of antagonists. Hexamethonium and dTC, acting as non­
competitive channel blockers, are believed to inhibit the entry of cytotoxic 
levels of Ca2+ in the cells. The belief that unregulated Ca2+ influx was 
responsible for the low a7 nAChR expression, was possibly supported by the 
higher levels of specific [125l]-aBgt binding seen in transfected cells 
expressing the Ca2+ impermeable chimaeric a7-5HT3 receptor. However, 
more efficient expression and ‘conformation-induced’ upregulation are 
alternative explanations for the increased levels of specific toxin binding seen
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in the cultured cells. The a7 homomeric nAChRs were further characterised 
by MLA This potent a7 specific alkaloid inhibited specific toxin binding in a 
saturable concentration dependent manner. The IC5o for MLA was similar to 
that reported for it at other a7 nAChRs. The use of FITC-aBgt permitted the 
fluorescent visualisation of the radioligand binding results. The inclusion of 
dTC in the post-transfection medium, resulted in an increase in the number 
and intensity of fluorescence labelled cells. The data also showed the HEK- 




The cDNA and amino acid sequence of chick a7. The HinD\\\ 
(AAGTTC), Psfl (CTGCAG), BamH\ (GGATCC), Xba\ (TCTAGA) and A/ofl 
(GCGGCCGC) sites used for subcloning are marked in italics. The signal 
peptide, Cys loop and vicinal cysteines are marked in bold. The four putative 
transmembrane domains are underlined. The use of the EcoRI (GAATTC, 
nucleotides 739 to 744) and Bgl\\ (AGATCT, nucleotides 902 to 913) sites will 
be discussed later (marked in bold italics).
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H i n D I I I  P s t l
AAGCTTCGGCTGCAGGTCGAAATTCGGCACGAGAGCCGACATCGCAGGGAGAGCCCCGCG 
10 20 30 40 50 60
CGGGCGCAGGAGGGGGCGGGGCGGCGAGAGGTCCGCGGCGGCGACGGAGGCTCCCGGCTC 
70 80 90 100 110 120
M G L R A L M L W L L A A  13
CGGCTGCTGCGGCTCCCGGAATGGGCCTCCGGGCGCTGATGCTGTGGTTGCTGGCGGCGG 
130 140 150 160 170 180
A G L V R E S L Q G E F Q R K L Y K E L  33
CGGGGCTCGTGCGCGAGTCCCTGCAAGGAGAGTTCCAAAGGAAGCTGTACAAGGAGCTGC 
190 200 210 220 230 240
L K N Y N P L E R P V A N D S Q P L T V  53
TGAAGAACTACAACCCTCTGGAACGACCAGTTGCAAATGACTCCCAGCCGCTCACTGTCT 
250 260 270 280 290 300
Y F T L S L M Q I M D V D E K N Q V L T  73
ATTTCACTCTCAGCCTCATGCAGATCATGGATGTGGATGAAAAGAATCAAGTATTAACAA 
310 320 330 340 350 360
T N I W L Q M Y W T D H Y L Q W N V S E  93
CAAACATCTGGCTACAAATGTACTGGACAGATCATTACTTACAGTGGAATGTGTCTGAAT 
370 380 390 400 410 420
Y P G V K N V R F P D G L I W K P D I L  113
ACCCTGGAGTGAAGAACGTCCGTTTTCCTGATGGACTGATTTGGAAGCCAGATATTCTTC 
430 440 450 460 470 480
L Y N S A D E R F D A T F H T N V L V N  133
TCTATAACAGTGCTGATGAAAGATTTGATGCTACATTTCACACTAATGTTTTAGTCAATT 
490 500 510 520 530 540
S S G H C Q Y L P P G I F K S S C Y I D  153
CTTCGGGACACTGCCAATATCTGCCACCAGGCATATTTAAAAGCTCATGCTACATAGACG 
550 560 570 580 590 600
V R W F P F D V Q K C N L K F G S W T Y  173
TGCGTTGGTTTCCATTTGATGTTCAGAAGTGCAATCTGAAGTTTGGATCTTGGACATATG 
610 620 630 640 650 660
G G W S L D L Q M Q E A D I S G Y I S N  193
GAGGCTGGTCCTTAGACTTACAAATGCAAGAAGCAGATATATCCGGCTATATTTCAAATG 
670 680 690 700 710 720
G E W D L V G I P G K R T E S F Y E C C  213
GAGAGTGGGATTTAGTAGGAATTCCTGGGAAGAGAACTGAGAGCTTTTATGAGTGCTGTA 
730 740 750 760 770 780
K E P Y P D I T F T V T M R R R T  L Y Y 233
AAGAAC CAT AC C CAGATATCACATTCACAGTAACCATGAGACGCAGAACTCTCTACTACG 
790 800 810 820 830 840
G L N L L I P C V L I S A L A L L V F L  253
GGCTCAACCTTCTTATTCCCTGTGTACTGATATCAGCACTTGCCTTATTAGTCTTTCTGC 
850 860 870 880 890 900
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L_ P A D S G E K I S L G I T V L L S L T  273
TTCCAGCAGACTCAGGAGAAAAGATCTCACTAGGTATAACAGTTTTATTGTCTCTCACCG 
910 920 930 940 950 960
V F M L L V A E I M P A T S D S V P L I  293
TCTTCATGTTACTCGTGGCTGAAATTATGCCAGCAACATCTGATTCTGTGCCCTTAATTG 
970 980 990 1000 1010 1020
A Q Y F A S T M I  I V G L S V V V T V I  313
CVCAGTATTTTGCCAGCACCATGATTATTGTTGGCCTCTCTGTTGTTGTCACTGTTATCG 
1030 1040 1050 1060 1070 1080
V L O Y H H H D P D G G K M P K W T R V  333
TTCTACAATACCATCATCACGATCCAGATGGGGGAAAAATGCCTAAATGGACAAGAGTCA
1090 1100 1110 1120 1130 1140
I  L L N W C A W F L R M K R P G E D K V 353
TCCTTCTGAATTGGTGTGCTTGGTTTCTGAGGATGAAGAGACCAGGGGAAGATAAAGTGC
1150 1160 1170 1180 1190 1200
R P A C Q H K Q R R C S L S S M E M N T 373
GTCCCGCCTGTCAACATAAACAGCGTCGATGCAGCCTGTCAAGCATGGAGATGAACACTG
1210 1220 1230 1240 1250 1260
V S G Q Q C S N G N M L Y I G F R G L D 393
TGAGTGGTCAGCAATGCAGTAATGGGAACATGCTGTATATTGGGTTTCGAGGGCTGGATG
1270 1280 1290 1300 1310 1320
G V H C T P T T D S G V I  C G R M T C S 413
GGGTTCACTGCACACCCACCACTGATTCAGGGGTGATCTGTGGGAGGATGACCTGTTCAC
1330 1340 1350 1360 1370 1380
P T E E E N L L H S G H P S E G D P D L 433
CAACAGAGGAAGAAAATCTTCTGCACAGTGGCCACCCCTCTGAAGGCGACCCAGATTTGG
1390 1400 1410 1420 1430 1440
A K I  L E E V R Y I  A N R F R D Q D E E 453
CTAAGATCCTGGAAGAGGTCAGATACATTGCAAACAGGTTCAGAGACCAGGATGAAGAAG
1450 1460 1470 1480 1490 1500
E A I  C N E W K F A A S V V D R L q L M 473
AAGCCATTTGCAACGAATGGAAGTTTGCAGCCTCTGTAGTAGATCGGCTCTGCTTGATGG
1510 1520 1530 1540 1550 1560
A F S V F T I I C T I G I  L M S A p N F 493
CATTTTCGGTCTTCACCATCATTTGTACAATTGGCATCTTAATGTCAGCACCAAACTTTG
1570 1580 1590 1600 1610 1620
V E A V S K D F A * 502
TAGAGGCTGTCTCTAAAGATTTTGCTTAACTCCTAACTATGATTTGATTCTCTGAAGTAT
1630 1640 1650 1660 1670 1680
CATATGTAGCAAATAAGAGTGTATTTTTTTTTGTTTGTTTGCTTGTTTTTAATGAGTACA 
1690 1700 1710 1720 1730 1740
CTGTATCTCATTGTCCTCTGTCTTTTGCCCCCCCCCCTATTCCCCCAGCATTCCTCTGAC 
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Figure 3.2a
The pRc/CMV vector used in the
COS-7 cell expression system.
P CMV CMV promoter 
BGH pA Bovine growth hormone 
polyadenylation signal 
SV40 ori SV40 origin of replication 
RSV LTR Rous sarcoma virus long 
terminal repeats 
Neomycin' Neomycin resistance marker 
SV40 pA SV40 polyadenylation signal 
ColE1 Colicinogeny factor E1 
Am picillin ' Ampicillin resistance marker 
((3-lactamase)
Figure 3.2b
The pMT3 vector used in the HEK-293 cell expression system.
SV40 pA SV40 polyadenylation signal




















The molecular structures of the nicotinic antagonists hexamethonium, 
d-tubocurarine, methyllycaconitine (MLA), 3-deoxy-18-0-desmethyl(2- 
aminobenzoyl) aconitine and 3-deoxy-18-0-desmethyl[2-(methylsuccinimido) 
benzoyl] aconitine. Lycoctonine is converted to MLA by the addition of a 
methylsuccinimido benzoate R group. Aconitine is a voltage gated Na+ 
channel activator (Rubin & Soderlund, 1992), modifications to its 
norditerpenoid core converted it to a potent nicotinic antagonist.
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Figure 3.4
Typical results from an experiment to iodinate aBgt (5pl samples of 
each 1ml fraction were counted).
E Total 125l (2mCi; fractions 5-19) 11642683cpm
E Total [125l]-aBgt (2.5nmol; fractions 5-13) 10670521 cpm
E peak [125l]-aBgt (fractions 6-8) 9670143cpm
E Free 125l (fractions 14-19) 972162cpm
In [125l]-ocBgt peak
Concentration of [125l]-aBgt
Concentration of 125l in peak
% Incorporation of 125l into aBgt 
Specific activity of [125l]-aBgt
_ £  peak [1251] - oBgt 2.5nmol 
^ T o ta l oBgt 3ml
9670143cpm 2.5nmol= ------------------— x ----------- = 0.76nmol/ml
10670521cpm 3ml
= 0.76pM
_ £ p e a k [125l]-oBgt x 2mCi 
2 'T o ta l1251 X 3ml
9670143cpm 2mCi _=  —  x ------- = 0.55mCi/ml
11642683cpm 3ml
Y  Total [125l]- oBgt 
= ^  Total I * 100% = 90-62%
Concentration o f1251 in peak 







a) The effect of different lengths of incubation on the results of 
binding assay performed on transfected COS-7 cells. The levels of specific 
toxin binding detected were shown, by Students' paired t test (P<0.02), not to 
be significantly different. Total binding replicate counts were between 7000- 
14000cpm and non specific replicate counts were between 4000-9000cpm. 
However, the individual level of replicate counts for both total and non­
specific binding displayed more inherent variability, the older the [125l]-aBgt 
was. Hence, [125l]-aBgt no older than 3 weeks, from date of iodination, was 
used in this study.
In these experiments n=2 and values are displayed as mean & range. Each 
value within one experiment consisted of 9 replicates.
b) Results from five [125l]-aBgt specific binding experiments 
performed on COS-7 cells transfected with a7 nAChR cDNA. None detected 
indicates that the experiment exhibited non specific binding greater than the 
total binding (in a fashion similar to that seen in untransfected and sham 
transfected cells), hence no detectable specific binding of [125l]-aBgt.
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Figure 3.6
a) The effect of including hexamethonium in the post-transfection 
medium, on the specific binding of [125l]-aBgt to COS-7 cells transfected with 
a7 cDNA. All concentrations of hexamethonium, with the exception of 10pM, 
increased specific binding significantly (P<0.05) over COS-7 cells transfected 
with a7 cDNA in the absence of hexamethonium. The specific binding of [125l]- 
aBgt exhibited by transfected cells in the presence of 10pM hexamethonium 
was not significantly different, by Students’ paired t test, from transfected 
cells in the absence of hexamethonium.
* - Significantly different from cells transfected in the absence of 
hexamethonium, P<0.05
** - No significant difference from cells transfected in the presence of 
50pM hexamethonium.
b) The effect of including 10pM dTC in the post-transfection 
medium, on the specific binding of [125l]-aBgt to COS-7 cells transfected with 
a7 cDNA. The inclusion of 10pM dTC led to a significant (P<0.05) 4 fold 
increase in the specific binding, over COS-7 cells transfected in the absence 
of dTC.
In all experiments n=3 and the values are displayed as mean ± an. Each 
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Comparison of specific binding of [125l]-aBgt between the COS-7 and 
HEK-293 expression systems transfected under the same conditions. The 
HEK-293 expression system exhibited significantly (P<0.02) greater specific 
binding under each experimental condition. The table summarises the 
changes in specific binding within each expression system, relative to cells 
transfected with a l  cDNA in the absence of antagonist.
In all experiments n=3 and the values are displayed as mean ± an. Each 
value within one experiment consisted of 12 replicates.
a7 Cells transfected with a7 cDNA
a7  + dTC Cells transfected with a l  cDNA and have 10pM dTC
included in the post-transfection medium 
<x7-5HT3 Cells transfected with a7-5HT3 cDNA
a7-5H T3 + dTC HEK-293 cells transfected with a7-5HT3 and grown under
the same conditions of a7 + dTC 
Untransfected + dTC Untransfected cells grown under the same conditions as 
a7 + dTC






























a7 + dTC 324.7% ± 150.0% 489.8% ± 123.0%
<x7-5HT3 262.2% ± 31.8% 334.1% ± 65.7%
<x7-5HT3 + dTC 345% ± 63.4%
Untransfected None Detected None Detected
Untransfected + 
dTC
None Detected None Detected
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Figure 3.8
Inhibition of specific binding of [125l]-aBgt to COS-7 and HEK-293 cells, 
transfected with a7 cDNA and with 10jxM dTC included in the post­
transfection medium, by MLA. The specific binding to transfected cells in the 
absence of MLA was designated as 100%. The IC5o for the a l  nAChR 
expressed in HEK-293 cells was 0.9±0.1nM. For the COS-7 cells, three 
curves were calculated. The dotted lines represent curves through the two 
points either side of a curve, passing through the mean of the two points 
(solid line). Since there were only two points in that region of the graph, the 
‘weighting’ given to each point could not be determined. Hence, the 
generation of a curve through the mean of the two points. The IC5o’s for each 
curve was (from left to right) 3.0±0.1nM, 9.9±6.9nM and 16.7±2.8nM 
respectively. The modified Hill equation used to generate the curves was-:
y = 100-(100/1+(k/x))n
k — IC 50
n = Hill number (this was generated for each curve and was =1.4)
In all experiments n=2 and the values are displayed as mean ± on. Each 




























0.01 0.1 1 10 100 1000
Concentration of MLA (nM)
103
Figure 3.9
Fluorescence labelling of untransfected and transfected COS-7 cells 
by FITC-aBgt. Total and non-specific binding were performed as detailed in 
Chapter 2. The upper two panels on each page were viewed under 
epifluorescence. The lower two panels on each page were viewed under 
inverted phase contrast (viewing magnification in brackets).
a) Untransfected COS-7 cells grown under same conditions as b (x200)
b) COS-7 cells transfected with a7 cDNA (x100)
c) COS-7 cells transfected with a7 cDNA with 10fiM dTC included in the
post-transfection medium (x100)
d) COS-7 cells with cx7-5HT3 cDNA (x100)
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a) Untransfected Total Binding Untransfected Non-specific Binding
105
b ) a7  Total Binding a7 Non-specific Binding
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C) a7+ 10pM dTC Total Binding a7+ 10(iM dTC Non-specific Binding
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d ) a7-5H T3 Total Binding a7-5H T3 Non-specific Binding
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Table 3.1
Inhibition of [125l]-ocBgt and [3H]-nicotine binding to nAChRs in different
tissues, by MLA. The 
Cheng-Prusoff 
equation was used to 
determine the IC50 
from the Kj and Kd 
(Cheng & Prusoff, 
1973). Data from 
Barrantes et al., 
1995; Wonnacott et 
al., 1993; Ward et al., 
1990; Macallan et al., 
1988.
Table 3.2
Inhibition of [125l]-aBgt and [3H]-nicotine binding to nAChRs in different 
tissues, by MLA and other related norditerpenoids. The IC5o values 
determined using the Cheng-Prusoff equation on data from Hardick et al., (in 
press).





Methyllycaconitine 3.3x10'9M 6.0x1 O^M 8.3x1 O^M
Lycoctonine 2.0x1 0'5M - >2x1 O^M
Aconitine 3.8x1 O^M >2x1 O^M >2x1 O^M
AB-Aconitine 6.2x10'7M >2x1 O^M >2x1 O^M
MSB-Aconitine 1 2.0x1 0'9M 8.4x10'5M >2x1 O^M
Not determined
AB-Aconitine 3-deoxy-18-0-desmethyl(2-aminobenzoyl) aconitine 
MSB-Aconitine3-deoxy-18-0-desmethyl[2-(methylsuccinimido)benzoyl] 
aconitine
Source of nAChRs MLA (IC60)
Cultured Hippocampal Cells 
(aBgt Sites)
15.8x10'9M
Brain P2 Membranes 
(aBgt Sites)
3.3x1 0'9M









Human Muscle Cell Line (TE671) 
(aBgt Sites)
1.3x10JM








4. Investigation of the Key Residues Involved in the
nAChR Subtype Specific Binding of MLA
4.1. Introduction
This chapter will investigate MLA’s nAChR subtype specificity, 
by comparing the MLA sensitivities and amino acid sequences of 3 nAChR a- 
subunits. From this data point mutations will be introduced into the a7 nAChR 
cDNA, in order to alter the binding of MLA to the expressed mutant receptor. 
However, the mutations should not effect the receptor’s ability to bind other 
nicotinic agonists and antagonists. Results of the site-directed mutagenesis 
and some electrophysiology data from the mutant receptors will be presented. 
The results will then be discussed in terms of providing information on the 
key residues involved in the specific binding of MLA.
4.1.1. The Nicotinic Pharmacophore
The notion of a pharmacophore model for nicotinic agonists was 
introduced in Chapter 1. Sheridan et al., (1986) defined 3 ‘essential groups’ 
that a pharmacophore, interacting at the ACh binding site, should possess:
A - A cationic centre; Quaternary nitrogen or protonatable nitrogen 
B - An electronegative atom; Carbonyl oxygen or aromatic nitrogen 
C - An atom to form a dipole with B; Carbonyl carbon or delocalising 
aromatic ring
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Their ‘Ensemble’ method of comparing the molecular structures of 
conventional nAChR agonists and antagonists, permitted the dimensions of 
the pharmacophore to be calculated. The distance between groups A & B and 
A & C were = 4.8A and 4.0A respectively. The distance between groups B & 
C was fixed at 1.2k, the length of a covalent carbonyl bond.
When the molecular structure of MLA was characterised by 
proton and 13C mass spectrometry (Jennings et al, 1986), the 
pharmacophore model was applied to it. Figure 4.1 shows the application of 
this model to MLA and a selection of other nicotinic ligands. The structure of 
MLA fitted the independently determined pharmacophore model and also 
fulfilled the stereochemical criteria for a nicotinic ligand, proposed 16 years 
before the discovery of its structure (Beer & Reich, 1970; Chothia & Pauling, 
1970).
The pharmacophore model predicts the same structure for 
agonist and antagonists. The model does not distinguish between the binding 
of an agonist or an antagonist, consequently it does not explain the difference 
in action of an agonist and an antagonist at the nAChR. Beers & Reich (1970) 
believed that the differences in agonist stereo-volume may have been, in 
part, responsible for receptor specificity. It was noted that nAChR antagonists 
tended to be of a larger stereo-volume when compared to the agonists (cf. 
structures in Williams et at., 1994). With this in mind, it was proposed that 
this larger stereo-volume, when docked at the agonist site, could inhibit the 
nAChR’s transition to the activated quaternary form (Sheridan et a!., 1986).
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This implies the possible involvement of amino acid residues not usually 
associated with agonist binding.
4.1.2. Criteria for the Choice of Point Mutations
The ‘Multiple Loop’ model of the ACh binding site was 
discussed in Chapter 1. Point mutations, synthetic peptide mediated toxin 
binding and immunological characterisation studies established the 3rd 
peptide loop (a180-a200) as important in determining nicotinic agonist 
recognition (Balass etal., 1993; McCormick et al., 1993; Galzi et al., 1991b). 
This loop contains the previously identified residues Y190, C192, C193 and 
Y198. Residues Y190 and Y198 have been shown to be involved in binding 
the quaternary N of nicotinic ligands (Aylwin & White, 1994; Sine et al., 
1994). Y190 has been suggested to be the site directly responsible for the 
anionic/cationic salt bridge interaction between the nAChR, and the 
quaternary or protonatable N of the nicotinic ligands. Thus it is assumed that 
this loop also binds the protonatable N of MLA (ie. essential group A in 
Figure 4.1).
The 3rd peptide loop amino acid sequence of the a7 subunit was 
aligned and compared with those of the Chick a1 and Locust ARL2 subunits 
(Figure 4.2). The Chick a1 subunit was isolated from nj/e nAChRs (Barnard et 
al., 1983). It is responsible for this receptor subtype’s sensitivity to nanomolar 
(nM) concentrations of aBgt and insensitivity to nM concentrations of MLA 
(Couturier et al., 1990a). The ARL2 a-subunit was isolated from Locust 
ganglia and forms homomeric nAChRs sensitive to nM concentrations of aBgt
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(like homomeric a l  nAChRs). The homomeric ARL2 nAChR is believed to be 
sensitive to nM concentrations of MLA (M. Amar, personal communication). 
This assertion is supported by MLA’s IC5o of 3.6nM at Locust ganglia (ie. 
where the ARL2 nAChR was isolated from (Table 3.1; Marshall et al., 1988)). 
Therefore in the 3rd peptide loop of a l  and ARL2 there would be similar 
amino acids that, by virtue of charge/polarity/size or a combination of these, 
facilitate the binding of MIA. Conversely in a1, these types of amino acids 
would be absent. From the sequence alignment, candidate residues were 
initially chosen on the criteria of charge and polarity (Figure 4.2).
4.2. Results
4.2.1. Design of the Oligodeoxyribonucleotide Primers for the
Point Mutations
The a l  nAChR’s 3rd peptide loop, with reference to the ARL2 
sequence, was pointed mutated to look more a1 like. Three point mutations 
were chosen (chick a1 numbering of amino acids used):
a7P182 to R (a7PR) Both a l  and ARL2 have the polar imino 
acid proline (P) at this position. The cis-trans isomerism of P is the rate- 
limiting step in the folding of many proteins (Brandts et al., 1975). Also this 
isomerism and P shape, make it an ideal residue for introducing kinks into the 
secondary structure of a helix or initiating a (3-turn (Voet & Voet, 1990). This 
residue was mutated to the positively charged arginine (R) in a1.
a7K184 to W(a7KW) a l  has a positively charged lysine (K) 
residue, whereas ARL2 has a negatively charged glutamate (E) at this
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position. However, a1 has non-polar tryptophan (W). The polarity of the 
charge at this position does not seem to affect the MLA binding ability of a l  
or ARL2. Replacement K by hydrophobic W  in a7 could affect this binding.
a7E187 to W (a7EW) Both a l  and ARL2 have negatively charged 
E at this position. a1 has W at this position. Using the same rationale as that 
used for the a7KW mutant, the a7 residue was mutated to the corresponding 
a1 residue.
Then the oligodeoxyribonucleotide primers were designed and synthesised, 
for use in PCR mediated site-directed mutagenesis (Figure 4.3).
4.2.2. PCR, Fragment Purification and Cloning
A ‘cassette’ method was used to insert the mutations in a7. The 
a l  nAChR cDNA was subcloned from the Flip vector into pBluescript II SK+, 
as described in Chapter 3. EcoRI and Bgl\\ restriction endonuclease sites, lie 
conveniently to the ends of the region of the receptor to be mutated (Figure 
3.1). Hence, wild-type fragments of the a l  nAChR cDNA were ‘excised’ and 
mutated fragments ‘inserted’ using these sites. For each point mutation, PCR 
production of mutant fragments was carried out using one of the mutation 
primers and the BR primer. The biotinylated PCR fragments were purified and 
digested attached to Dynabeads, with EcoRI as the first digest and BgIM as 
the second. The digested mutated fragment was then cloned into an 
EcoR\/Bgl\\ prepared pBluescript II SK+ a l  vector. Clones, from competent 
cells transformed with the mutant a l  nAChR cDNA, were then sequenced.
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4.2.3. Sequencing the Mutants
The proposed mutant clones were sequenced, forward past the 
Eg/ll site and reverse past the EcoRI site, as described in Chapter 2. For 
forward sequencing the corresponding mutation primers were used. All 
reverse sequencing used the Sequencing primer (Figure 4.3). Each 
sequencing reaction was performed in triplicate and 3 clones were identified 
(ie. one for each mutant), by reverse sequencing (Figure 4.4). The forward 
sequencing of each clone produced a sequence identical to the wild-type a7, 
extending at least 10 base pairs past the Eg/ll site (results not shown). The 3 
mutant a7 clones were each subcloned into the pRc/CMV expression vector, 
as in Chapter 3. This gave 3 mutant expression clones pRc/CM\/a7KW (a7K- 
W), pRc/CMVa7EW (a7E-W) and pRc/CMVa7PR (a7P-R).
4.2.4. Electrophysiology of the Mutants
The three mutants were to be characterised in the cultured cell 
expression system, developed in Chapter 3. However, because of the initial 
low levels of expression detected in the cultured cell expression system and 
the time taken to develop a solution to this, preliminary characterisation of the 
mutants was performed in Xenopus oocytes. I am indebted to Drs. Amar and 
Wheeler for carrying out these electrophysiological studies. Wild-type and 
mutant a7 nAChRs (all using the pRc/CMV expression vector) responses to 
nicotine and ability to bind MLA, were investigated under voltage-clamp 
conditions.
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The Xenopus oocyte expressed homomeric a7 nAChR 
desensitised very rapidly, when challenged with 100pM nicotine (displaying 
=3.2pA current; Figure 4.5). The EC5o for nicotine at this nAChR was 35pM, 
with a current-voltage curve that inwardly rectifies at more positive potentials 
(Figures 4.6 & 4.7). These results are similar to those reported by Amar et al., 
(1993) and Couturier eta!., (1990a) for the homomeric a7 nAChR, expressed 
in Xenopus oocytes. This indicates that the pRc/CMV vector does not effect 
the expression of the a7 nAChR.
No response to 100pM nicotine was seen in Xenopus oocytes 
injected with the a7P-R mutant (S. Wheeler, personal communication). The 
a7E-W mutant responded to challenge with 10pM, 25pM and 100pM nicotine 
(Figure 4.8). At 100pM nicotine, the current was equal to that seen in 
Xenopus oocytes expressing the wild-type homomeric a7 nAChR. The above 
data^wa^included in a dose-response curve to nicotine for the a7E-W mutant 
nAChR (Figure 4.9). The EC5o of 60pM for nicotine was very similar to that for 
the wild-type homomeric a7 nAChR. No work to determine the a7E-W mutant 
nAChR’s sensitivity to MLA has been performed yet.
Xenopus oocytes injected with the a7K-W mutant produced 
responses when with 100pM nicotine. However, the magnitude of the current 
produced was =30 times less than that seen for the wild-type or a7E-W 
mutant (Figure 4.10). Challenge with 500pM nicotine did not appreciably 
increase the current observed. Figure 4.10 also records the response of this 
mutant to MLA. Preincubation of the a7K-W mutant with 10nM MLA, did not 
affect the response elicited by a 100pM nicotine challenge. This would
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suggest that the a7K-W mutant nAChR was not blocked by a concentration of 
MLA proposed to be around its IC5o- Unfortunately, this experiment was only 
performed on one cell.
4.3. Discussion
MLA possesses the 3 essential groups determined by the 
‘Ensemble’ pharmacophore model (Figure 4.1). The validity of the ‘Ensemble’ 
method can be tested by comparing the mAChR and nAChR 
pharmacophores. mAChRs, like nAChRs, binds ACh at its conventional 
agonist site. Thus, the pharmacophore models and consequently the 
molecular structures of the ligands of the nAChR and mAChR, should share 
some similarities (Beers & Reich, 1970). This is aptly demonstrated by the 
homomeric a9 nAChR, that binds ACh and nicotine, and also the muscarinic 
ligands atropine and OXO-M (Elgoyhen eta!., 1994).
Recognition of the MLA molecule, by the a7 nAChR, is believed 
to be determined within the 3rd peptide loop (amino acids a180-a200) of the 
‘Multiple loop’ model of the ACh binding site. This is the same region of the 
a7 nAChR, that has been shown to be involved in binding the nicotinic ligand 
pharmacophore’s essential group A; the quaternary or protonatable N. 
Although sharing the same pharmacophore, agonists and antagonists have 
different modes of action at the nAChR. This could be explained by 
antagonists tending to be sterically larger that agonists. This increased 
stereo-volume might interact with amino acids, in the ACh binding site, not 
associated in the binding of agonists. This may also help to explain the
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preference of competitive antagonists to bind to, and stabilise the resting or 
one of the desensitised states of the nAChR (Williams et al., 1994; McCarthy 
& Stroud, 1989; see Figure 1.4). These residues may be responsible for 
MLA’s nAChR subtype specificity (ie. nM sensitivity at a7 and ARL2 nAChRs 
and insensitivity at a1 containing nAChRs).
The a7 nAChR amino acids which were to be mutated to the 
residues present in the a1 nAChR, were chosen by comparing and 
contrasting the 3rd peptide loop sequences of a7, a1 and ARL2 (Figure 4.2). 
The mutations should modulate the a7 nAChR’s MLA binding, without 
affecting its ability to recognise nicotine (Figure 4.3). Three mutants were 
chosen and created by the use of PCR and mismatched primers. These were 
a7P-R (position a182), a7K-W (position a184) and a7E-W (position a187). 
The preliminary nature of these data from the mutants should be stressed. 
Consequently, the conclusions drawn below would still need further 
investigation.
Wild-type and mutant a7 nAChR responses to nicotine were 
observed in Xenopus oocytes injected with their cDNAs. Xenopus oocytes 
injected with the wild-type a7 nAChR, gave responses to nicotine almost 
identical to those reported for the homomeric a7 nAChR in the literature. 
Thus it was assumed that this expression system was investigating 
homomeric a7 nAChRs also. A previous study on point mutations introduced 
into the a180-a200 region of the a7 nAChR concluded that they did not affect 
the receptor’s ability to form homomers (Galzi etal., 1991b).
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Xenopus oocytes expressing the a7E-W mutant produced a 
response to nicotine with a similar EC5o to that seen for the wild-type nAChR 
(Figure 4.9). However, the point mutation seemed to produce receptors that 
desensitised at a slower rate than the wild-type (Figure 4.8). The residue at 
position a187 is believed to be involved in the conferring aBgt resistance in 
snake and mongoose nAChRs (Barchan eta l, 1992). In mongoose a1, N187 
replaces the chick a1 W187, thus introducing a putative glycosylation site. If 
glycosylated, the carbohydrate ‘tree’ could sterically hinder the binding of the 
bulky aBgt peptide. However, the importance of this site is called into 
question when the snake a1 and human a1 sequences are compared. Both 
subunits possess S187 at this position, yet snake a1 containing nAChRs are 
aBgt insensitive and human a1 containing are aBgt sensitive (Barchan et al., 
1992; Chaturvedi etal., 1992).
The a7K-W mutant produced nAChRs that had a marked 
reduction in their response to nicotine, compared to the wild-type (Figure 
4.10). The current produced was similar to that reported for the nj/e nAChR in 
Xenopus oocytes (Mishina et al., 1984). The reasons for this are unknown. 
However, the replacement of an aliphatic charged residue by a more rigid 
hydrophobic one, may effect the allosteric conveyance of the ‘agonist/binding 
site conformation signal’ through the receptor, to activate the channel. A 
result, seen only in one cell, indicates that the a7K-W mutant is insensitive to 
10nM MLA. This result needs further investigation. If repeatable, this data 
would suggest that a184 may be one of the sites fundamental in determining 
the nAChR subtype specificity of MLA. It should be noted that in the MLA and
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aBgt sensitive a-subunits, a184 is occupied by a charged residue. In MLA 
insensitive a-subunits, the position is held by hydrophobic or polar residues 
(Sargent, 1993). Possible predictions could be made about the MLA 
sensitivities of a8 and a9 subunits, both of which are aBgt sensitive 
(Elgoyhen et al., 1994; Schoepfer et al., 1990). a8, which has positively 
charged lysine at position a184, should be MLA sensitive. a9, which has 
hydrophobic valine at position a184, should be MLA insensitive.
Xenopus oocytes injected with the a7P-R mutant, failed to 
respond when challenged with nicotine. Helekar et al., (1994) emphasised 
the importance of prolines being in the correct cis-trans conformation for 
successful formation of the binding site and surface expression. The loss of 
the proline was, in positional terms, relatively conservative (ie. the residue 
replacing the proline (R), was present in the same position in another a - 
subunit). Thus it seems more probable, as Galzi et al., (1991b) have argued, 
that the failure to respond was due to the point mutation destroying the ACh 
binding site conformation. However, another reason possibly lies in the 
quality of the Xenopus’ oocytes. Problems were experienced with batches of 
Xenopus oocytes during this study. The remedy, of changing the husbandry 
of Xenopus, came too late for the completion of this study.
However, these preliminary data highlight some of the potential 
work that could be performed in the cultured cell expression system. Several 
derivatives based on the norditerpenoid core structures of lycoctonine and 
aconitine have been synthesised (Blagbrough et al., 1994b; Coates et al., 
1994; Hardick et al., 1994). The cultured cells expressing the a7 nAChR
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could be used to screen for nicotinic activity in these compounds. The 
molecular structures of the active compounds could then be used to refine 
the model of the ACh binding site.
4.3.1. Summary
Agonists and antagonists that bind to the ACh binding site on 
nAChRs, share the same pharmacophore as predicted by the ‘Ensemble’ 
model. The 3rd peptide loop, of the proposed ‘Multiple loop’ model of the ACh 
binding site, is believed to be important in determining the recognition of 
nicotinic ligands. The steric size of antagonists may bring into play residues, 
in the 3rd peptide loop, that are not associated with the binding of agonist, of 
smaller stereo-volume. Thus, these residues may underpin the nAChR 
subtype specificity of the competitive antagonist MLA. a7 and ARL2 form 
homomeric nAChRs sensitive to nM concentrations of MLA and aBgt. a1 
containing nAChRs are sensitive to nM concentrations of aBgt, but 
insensitive to nM concentrations of MLA.
With reference to the ARL2 sequence, three amino acid 
residues in the a7 nAChR 3rd peptide loop were mutated to the corresponding 
ones in a1. Preliminary results showed that the a7P-R mutant produced no 
response to nicotine, which was possibly due to the destruction of the ACh 
binding site. The a7E-W mutant responded to nicotine in a similar manner to 
the wild-type homomeric a7 nAChR. The only MLA experiment was carried 
out on one Xenopus oocyte, expressing the a7K-W mutant. This showed the 
mutant to be insensitive to MLA. If this is a repeatable observation, the
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mutation reveals a site in the 3rd peptide loop involved in the determination 
of MLA sensitivity. This study should be repeated extensively in order to 
verify the conclusions drawn.
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Figure 4.1
Application of the ‘Ensemble’ pharmacophore model of a nicotinic 
ligand to the molecular structures of nAChR agonists Acetylcholine, Nicotine, 
Cytisine and the antagonists MLA and Strychnine. All molecules fitted within 
the model’s parameters. The pharmacophore calculations were not performed 
on Anatoxin-a. However, the molecule possesses the 3 essential groups (A, 
B & C) discussed in the text and molecular dimensions similar to 
acetylcholine (Swanson etal., 1986) (Datafrom Wonnacott etal., 1983; Ward 
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Chick a7 Yes Yes Yes
Chick a1 Yes No Yes
Locust ARL2 Yes Yes Yes
Figure 4.2
Amino acid sequence alignment of 3rd peptide loops from Chick a7, 
Chick a1 and Locust ARL2. The full a l  and a1 cDNA sequences are 39% 
and 44% homologous with the full ARL2 sequence, respectively. Sequences 
were aligned by Cockcroft et al., (1992), using the ’BIOSITE’ program. 
Residues identified in previous studies as being involved in nicotinic ligand 
binding, are highlighted in italics. Charged and polar amino acids are 
highlighted in bold or underlined, respectively. These residues are the 
potential sites for the point mutations (explained in the text). The table 
summarises the pharmacological criteria for choosing the a-subunits used.
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Figure 4.3
a) Sequences of the oligodeoxyribonucleotide primers used to 
generate and sequence the mutant a7 nAChRs. Primers a7PR, a7KW and 
a7EW bind and introduce the point mutations at the beginning of the 3rd 
peptide loop. The ‘Universal M13 Reverse’ primer (BR primer) bound to the 
multiple cloning site of pBluescript II SK+ (=84 base pairs upstream of the 
BamHI site). The Sequencing primer bound from nucleotide 876 to nucleotide 
858 (see Figure 3.1).
The EcoRI site is underlined. The mutated residues and sequences are in 
bold.
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a7KW Primer (36mer)
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a7EW Primer (51mer)
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Figure 4.4
The sequences of the mutated 3rd peptide loops in the a7KW, a7EW 
and a7PR clones. The Sequencing primer sequences the complementary 
cDNA strands of the mutated receptors. Consequently, the sequence read 
(ie. read from the bottom to the top of the autoradiograph) will be the 
complementary of that seen in the a7 cDNA sequence.
The EcoRI site is underlined. The mutated residues and sequences are in 
bold.
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A G C T
Mutant a7K-W
K C C E Y F S E T R W G
CTTTACAGCACTCATAAAAGCTCTCAGTTCTCCACCC
P I G V L 
AGGAATTCCTACTAAA 
E co R I
Mutant a7E-W
K C C E Y F S W T R K G
CTTTACAGCACTCATAAAAGCTCCAAGTTCTCTTCCC
P I G V L 
AGGAATTCCTACTAAA 
E co R I
Mutant a7P-R
K C C E Y F S E T R K G
CTTTACAGCACTCATAAAAGCTCTCAGTTCTCTTCCC






Response of the homomeric a l  nAChR, expressed in Xenopus 
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Figure 4.6
Dose response curve to nicotine of homomeric a7 nAChRs expressed 
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The current-voltage relationship of the homomeric a7 nAChR 
expressed in Xenopus oocytes. This illustrates the voltage dependence of 
nicotine induced currents in the a7 nAChR.
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Figure 4.8
Responses of the a7E-W mutant nAChR expressed in Xenopus 
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Figure 4.9
Dose response curve to nicotine of the a7E-W mutant nAChR 
expressed in Xenopus oocytes. The EC5o is 60pM, with an Hill number of 1.0. 
Three cells were used.
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Figure 4.10
Response of the a7K-W mutant nAChR, expressed in Xenopus 
oocytes, to 100pM and 500pM nicotine. The response of this mutant to 
100pM nicotine after a 10 minute preincubation with 10nM MLA, was 





In 1987, Schuetze and Role said “Compared to muscle 
nAChR(s), little is known about neuronal nAChRs”. Eight years on, the 
neuronal nAChRs subunits remain, relative to their nj/e counterparts, poorly 
characterised. However, the application of molecular, immunological and 
physiological techniques have slowly rectified this. Neuronal nAChR subunits 
have been isolated from human, chicken, rat, bovine, goldfish, Drosophila 
and locust. (Sargent, 1993; Marshall etal., 1990; Whiting & Lindstrom, 1988). 
One of the major drawbacks during these studies has been the lack of 
suitable nAChR receptor subtype specific probes.
aBgt has been used as a standard probe for nj/e nAChRs for 
many years. The presence of aBgt binding sites in the brain, indicated that 
the toxin could be possibly used as a probe for neuronal nAChRs. The 
existence of aBgt binding neuronal nAChRs was called into doubt, when they 
were found not to coincide with the location of high affinity ACh and nicotine 
binding sites (Clarke, 1992). Cloning of the a7, a8 and a9-subunits of the 
neuronal nAChRs and the subsequent electrophysiological studies performed 
on them, demonstrated that aBgt binding sites were part of functional 
nAChRs.
A question that then arises is, why have so many subunits 
contributing to one receptor family? Possible answers to this come from 
investigating the roles of the neuronal nAChRs. In the brain, the glutamate
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receptors constitute the major excitatory transmission system (Hollmann & 
Heinemann, 1994). nAChRs seem, in several brain systems, to coordinate 
the release of other neurotransmitters. The a402 nAChR subtype 
predominates in the brain, and has been implicated in modulating the 
neuronal release of ACh, GABA, glutamate and dopamine (Beani etal., 1989; 
Wonnacott, 1989). The involvement of aBgt binding neuronal nAChRs in the 
expression of neurotrophic factors and neurite retraction, suggests a role for 
a7 containing nAChRs in synaptic maintenance (Freedman et a!., 1993; 
Lipton & Kater, 1989). Rather than having a separate receptor/agonist system 
for each cellular response, a single tissue may give several different 
responses to one neurotransmitter, depending on the number of receptor 
subtypes it expresses. This highlights a ‘reductionism’ theme, that is
extended to the architectural homology of the subunits within the LGIC
superfamily (eg cys-loops, Figure 1.2). It is assumed that the receptors within 
the superfamily function along similar principles. Thus information on the 
working of one receptor, could be generally applied to the rest of the 
superfamily. An example of superfamily receptors functioning along similar 
principles would be the chimaeric a7-5HT3 receptor, that possesses nicotinic 
ligand binding character and an ion channel with serotonergic character 
(Eisele etal., 1993).
5.2. Expressing the a7 Homomeric nAChR
The ability of a7 subunits to form a functional homomeric
nAChR, make it an ideal model on which to study LGIC function. The
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subunits are relatively easy to manipulate and give good responses when 
expressed in Xenopus oocytes. The response of the Xenopus oocyte 
expressed homomeric a7 nAChRs to nicotine (Figure 4.5), is very similar to 
the Type IA response characterised in whole cell recordings from 
hippocampus (Alkondon et ai, 1994; Alkondon & Albuqueruqe, 1993). This 
indicates the presence of electrophysiologically similar native a7 nAChRs. 
However, the evidence does suggest that the native a7 nAChRs are 
homomeric (Puchacz et a!., 1994; Anand et a!., 1993a). The rapid 
desensitisation of the a7 nAChRs indicates a role in responding to acute 
release of ACh (Couturier etal, 1990a).
The modulation of intracellular Ca2+ levels seems to be 
associated with the action of a7 nAChRs. Permeability to Ca2+ is a well 
characterised property of neuronal nAChRs. <x7 nAChRs were shown to be 
particularly Ca2+ permeable, with a large proportion of the response seen in 
Xenopus oocytes, being due to the activation of Ca2+ dependent Cl' channels 
(Seguela et ai, 1993).
The establishment of a stable cell line expressing a7 nAChRs, 
like the M10 cell line for the a4p2 nAChR (Whiting et a!., 1991), would permit 
a greater critical study of the receptor’s biochemical, pharmacological and 
physiological properties, than would be possible in Xenopus oocytes or in 
situ. Puchacz etal., (1994) reported the successful production of a stable cell 
line expressing the homomeric a7 nAChRs. However, the SH-SY5Y cell line 
used also expressed other native nAChR subtypes (Lukas etal., 1993; Gould 
et ai, 1992). The use of a ‘nAChR naive’ cell line means that any nicotinic
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character, subsequently exhibited by the transfected cell line, would be as a 
result of the transfecting cDNA(s)’ product(s). Transient expression is 
sometimes used as a intermediate step in between Xenopus oocyte and 
stable expression of a nAChR (Sine & Claudio, 1991b). The transient 
expression system allows the optimisation of the receptor’s transfection, 
expression and maintenance conditions prior to stable transfection.
The COS-7 and HEK-293 cell lines, both naive in terms of the 
specific binding of [125l]-cxBgt (see Chapter 3), were transiently transfected 
with a7 nAChR cDNA. Low levels of receptor expression (ie. as determined 
by the specific binding of toxin) were detected. This result was compared to 
the low levels of expression seen in cultured cells, transiently transfected with 
subunits of the NMDA glutamate receptor. The reason for the low expression 
was traced to ‘Ca2+ excitotoxicity’ (Rothman & Olney, 1987). Glutamate in the 
culture medium, led to prolonged opening of NMDA receptor and unregulated 
influx of Ca2+ through the channel. This resulted in low receptor expression 
and eventually cell death. Ca2+ excitotoxicity has also been cited as 
attributing to ischemic muscle cell death (Leonard & Salpeter, 1979), via a 
proposed mechanism that involves VDCCs and shares some similarities to 
that described by Wonnacott et ai, (1989) for presynaptic nAChR receptor- 
mediated neurotransmitter release. For the NMDA receptors, this problem 
was initially overcome by the inclusion of antagonists in the post-transfection 
medium.
No conventional nicotinic agonist was identified in the DMEMg 
or DMEM/F12g. However, that does not exclude the possibility of the
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presence of a ‘physostigmine-like’ allosteric channel activating ligand 
(Schrattenholz et at, 1993). Sites on the nAChR for nicotinic ligands other 
than at the ACh binding site and ion channel, were proposed by Hiedmann et 
ai, (1983). Experimental support for such sites was observed when cells 
expressing the a7 nAChR and grown in the presence of desensitising 
concentrations of nicotine, exhibited little if any expression (J-L. Galzi, 
personal communication). The ability to activate the channel in the presence 
of desensitising concentrations of agonist, is a property of physostigmine at 
its binding site (Pereira et ai, 1993). However, the physostigmine mediated 
channel activation was inhibited by the use of a channel blocker (Okonjo et 
ai, 1991).
Channel blocking concentrations of the nicotinic antagonists, 
hexamethonium and dTC, were included in the post-transfection medium. 
Both antagonists increased the level of specific toxin binding, presumably 
due to the increased levels of receptor expression (Figures 3.7 & 3.9). The 
levels of expression could have been also monitored by the use of a Northern 
blots, to assay the cellular levels of a7 mRNA or an anti-a7 
immuofluorescence assay (Barrantes et ai, 1995; Couturier et ai, 1990a). 
Hexamethonium was not as effective as dTC, possibly due to its higher IC5o 
or it becoming cytotoxic at concentrations above 50pM or more likely not 
being as efficacious a drug as dTC. An alternative explanation for dTC’s 
success at increasing the level of specific toxin binding could be that as well 
as blocking the channel, dTC induces a conformational change in the nAChR.
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This conformational change, along with the presence of the ‘allosteric 
channel activator’, could be a trigger that leads to receptor upregulation.
The successful expression of the Ca2+ impermeable chimaeric 
a7-5HT3 receptor, may have indicated that Ca2+ influx was possibly 
responsible for the low expression of the a l  nAChR. However, the 
transfected cells did not exhibit classical features of cytotoxicity due to Ca2+ 
(ie. radical decreases in viable cell number and total protein present). In 
transfected cells, Ca2+ influx could be monitored by the use of a Ca2+- 
sensitive dye (such as fura-2) and confocal microscopy. This technique would 
enable the visual quantification, over time, of the amount of Ca2+ entering the 
cells. It would also permit the comparison of Ca2+ levels within cells 
transfected in the presence or absence of antagonists. The data seems to 
indicate that the presence of antagonists promotes more efficient surface 
expression of the a l  nAChR. Consequently, the results seen with transfected 
cells expressing the chimaeric a7-5HT3 receptor may have been due to the 
receptor, like the 5HT3 receptor, being more efficiently expressed in cultured 
cells than the a7 nAChR. Comparison of the relative increases in specific 
toxin binding seen in each expression system, indicate that the HEK-293 
expression was more efficient than the COS-7 expression system.
5.3. MLA, the Pharmacophore and the Mutants
The nicotinic character of the a7 nAChRs expressed in the 
cultured cells, was confirmed by the potent inhibition of specific toxin binding 
by nanomolar (nM) concentrations of MLA (Figure 3.8). Although sterically
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larger than the agonists ACh and nicotine, MLA fulfils the criteria of the 
'Ensemble' pharmacophore model for nicotinic ligands.
The potency of MLA at different nAChR subtypes is probably 
determined by amino acids not directly involved in binding the 
pharmacophore’s essential groups. Three potential amino acids, in the 3rd 
peptide loop of the a7 nAChR, were selected and mutated. The mutants were 
characterised in Xenopus oocytes, although the initial intention was to use 
the cultured cell expression system to accomplish this.
Preliminary data from the a7K-W and a7E-W mutants, showed 
that they formed functional nAChRs. These data also showed that the a7K-W 
mutant was insensitive to MLA (discussed in Chapter 4). The failure to detect 
responses to challenges by nicotine in Xenopus oocytes purporting to 
express the a7P-R mutant, might be due to the production of a non-functional 
nAChR or poor cell quality. However, these results need to be repeated in 
order to confirm the conclusions drawn above. The data collected on the 
mutants so far, indicates that expression in the developed cultured cell 
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